{
	"145": {
		"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
		"sources": [
			"civic",
			"oncokb"
		],
		"association_set": [
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/158",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/S768I",
				"source": "oncokb",
				"description": "FDA-approved biomarker and drug in this indication",
				"drug_labels": "AFATINIB,Erlotinib,GEFITINIB",
				"variant_name": "S768I",
				"source_link": "http://oncokb.org/#/gene/EGFR/variant/S768I",
				"evidence_label": "A",
				"response_type": "NA",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/142",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/158"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/158",
						"type": "Predictive",
						"description": "1",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17285735",
							"http://www.ncbi.nlm.nih.gov/pubmed/28336552",
							"http://www.ncbi.nlm.nih.gov/pubmed/25521405",
							"http://www.ncbi.nlm.nih.gov/pubmed/26051236"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Non-Small Cell Lung Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/158"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/99",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/158"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/98",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/158"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/97",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/158"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/299",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/S768I",
				"source": "oncokb",
				"description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved",
				"drug_labels": null,
				"variant_name": "S768I",
				"source_link": null,
				"evidence_label": null,
				"response_type": null,
				"evidence_level": null,
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/265",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/299"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/299",
						"type": "Predisposing",
						"description": "Gain-of-function",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19536777",
							"http://www.ncbi.nlm.nih.gov/pubmed/29141884",
							"http://www.ncbi.nlm.nih.gov/pubmed/16205628",
							"http://www.ncbi.nlm.nih.gov/pubmed/25521406",
							"http://www.ncbi.nlm.nih.gov/pubmed/25521405",
							"http://www.ncbi.nlm.nih.gov/pubmed/23242437",
							"http://www.ncbi.nlm.nih.gov/pubmed/19147750",
							"http://www.ncbi.nlm.nih.gov/pubmed/18676761",
							"http://www.ncbi.nlm.nih.gov/pubmed/23912954",
							"http://www.ncbi.nlm.nih.gov/pubmed/25179728",
							"http://www.ncbi.nlm.nih.gov/pubmed/25130612"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Oncogenic",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/299"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/409",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/4273/summary#evidence",
				"source": "civic",
				"description": "In stage IV lung adenocarcinoma patients (n=2) harboring EGFR S768I mutation, EGFR S768I was associated with progressive disease after 1 month of erlotinib monotherapy; the patient was previously treated with standard chemotherapy.",
				"drug_labels": "Erlotinib",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/371",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/409"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/409",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22895145"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4273",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/409"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/199",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/409"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/410",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/4274/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a Ba/F3 cell line expressing EGFR S768I demonstrated reduced sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing a known sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing cell proliferation, the IC50 of erlotinib for EGFR S768I and EGFR L858R expressing cells were 250 nmol/L and 6 nmol/L, respectively.",
				"drug_labels": "Erlotinib",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/372",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/410"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/410",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19147750"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4274",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/410"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/200",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/410"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/411",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/4185/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a NIH3T3 cell line expressing EGFR R108K demonstrated increased sensitivity to erlotinib treatment comparable to NIH3T3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors). Sensitivity was determined by assessing EGFR auto-phosphorylation.",
				"drug_labels": "Erlotinib",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/373",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/411"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/411",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17877814"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4185",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/411"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/201",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/411"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/412",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/2906/summary#evidence",
				"source": "civic",
				"description": "S768I mutations in exon 20 of the EGFR gene are rare and are typically seen in conjunction with sensitizing EGFR mutations. Because of this mutation's rarity and the variability of responses of treated cases, its exact prognostic and predictive role is not fully understood. In our experience, S768I mutations in isolation do not necessarily confer sensitivity to erlotinib, but in conjunction with sensitizing EGFR mutations, S768I mutations do not restrict efficacy.",
				"drug_labels": "Erlotinib",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/374",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/412"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/412",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27211795"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2906",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/412"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/202",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/412"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/413",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/2616/summary#evidence",
				"source": "civic",
				"description": "In vitro studies showed that cells with S768I mutation had moderate sensitivity (IC50=90-315nM) to gefitinib , in comparison to the del747-753insS (IC50= 7nM) or L858R (IC50=12-20nM) mutations that confer high gefitinib sensitivity, and to the T790M mutation (IC50>2000nM) which confers gefitinib resistance.",
				"drug_labels": "GEFITINIB",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/375",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/413"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/413",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16205628"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2616",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/413"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/203",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/413"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/414",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/2615/summary#evidence",
				"source": "civic",
				"description": "Partial response to gefitinib was achieved in two non-small cell lung cancer patients having a S768I mutation with concomitant G719C mutation.",
				"drug_labels": "GEFITINIB",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/376",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/414"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/414",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15998907"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2615",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/414"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/204",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/414"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/415",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/2614/summary#evidence",
				"source": "civic",
				"description": "In response to gefitinib treatment, lung adenocarcinoma patients with somatic EGFR S768I mutation had longer median progression-free survival when there was a concomitant L858R mutation or in-frame deletion in exon 19, in comparison to those with other concomitant mutations (12.7mo 95%CI 3.4-22.0mo vs. 4.9mo 95%CI 1.5-8.3mo, P=0.048, log-rank test). Partial response to gefitinib was achieved in two non-small cell lung cancer patients having a S768I mutation with concomitant G719C mutation.",
				"drug_labels": "GEFITINIB",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/377",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/415"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/415",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19060236"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2614",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/415"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/205",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/415"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/416",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/1394/summary#evidence",
				"source": "civic",
				"description": "A patient with metastatic lung adenocarcinoma was found to harbor EGFR T790M and S768I mutations when acquired resistance developed after 8 years of erlotinib treatment. Analysis of original tumor samples from 2001 and 2003 were found to also harbor the S768I (but not T790M) mutation. Three-dimensional visualization showed the 768 position to be outside of the erlotinib binding position.",
				"drug_labels": "Erlotinib",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/378",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/416"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/416",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25521405"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1394",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/416"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/206",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/416"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/417",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/145",
					"name": "S768I",
					"description": "EGFR S768I",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249005,
					"end_pos": 55249005,
					"ref": "G",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249005G>T",
					"hgvs_c": "NM_005228.3:c.2303G>T",
					"hgvs_p": "NP_005219.2:p.Ser768Ile",
					"dbsnp_ids": [
						"121913465"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/562/summary/evidence/1395/summary#evidence",
				"source": "civic",
				"description": "Case report of an 81-year old man with lung adenocarcinoma and EGFR S768I mutation. The patient then received chemotheraoy (vinorelbine) and showed stable disease. Gefitinib was administered when disease progression was noted 4 months later and the patient was followed-up without signs of disease progression for 461 days.",
				"drug_labels": "GEFITINIB",
				"variant_name": "S768I",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/562/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/379",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/417"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/417",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20522446"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1395",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/417"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/207",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/417"
					}
				]
			}
		],
		"name": "S768I",
		"description": "EGFR S768I",
		"biomarker_type": "missense_variant",
		"so_hierarchy": [
			"SO:0001060",
			"SO:0001537",
			"SO:0001878",
			"SO:0001564",
			"SO:0001576",
			"SO:0001791",
			"SO:0001580",
			"SO:0001818",
			"SO:0001650",
			"SO:0001992"
		],
		"soid": "SO:0001583",
		"so_name": "missense_variant",
		"reference_name": "GRCh37",
		"refseq": "NM_005228.3",
		"isoform": "ENST00000275493",
		"chromosome": "7",
		"start_pos": 55249005,
		"end_pos": 55249005,
		"ref": "G",
		"alt": "T",
		"hgvs_g": "NC_000007.13:g.55249005G>T",
		"hgvs_c": "NM_005228.3:c.2303G>T",
		"hgvs_p": "NP_005219.2:p.Ser768Ile",
		"dbsnp_ids": [
			"121913465"
		],
		"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249005G>T?assembly=hg19",
		"gene": {
			"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
			"entrez_id": 1956,
			"ensembl_gene_id": "ENSG00000146648",
			"symbol": "EGFR",
			"uniprot_ids": [
				"P00533"
			],
			"location": "7p11.2",
			"sources": {
				"civic": null,
				"oncokb": null
			}
		}
	},
	"130": {
		"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
		"sources": [
			"civic",
			"oncokb"
		],
		"association_set": [
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/143",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/T790M",
				"source": "oncokb",
				"description": "Standard of care biomarker predictive of resistance to an FDA-approved drug in this indication",
				"drug_labels": "AFATINIB,Erlotinib,GEFITINIB",
				"variant_name": "T790M",
				"source_link": "http://oncokb.org/#/gene/EGFR/variant/T790M",
				"evidence_label": "A",
				"response_type": "resistant",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/127",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/143"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/143",
						"type": "Predictive",
						"description": "R1",
						"publications": [
							"http://library.iaslc.org/search-speaker?search_speaker=17991",
							"http://www.ncbi.nlm.nih.gov/pubmed/24478319",
							"http://www.ncbi.nlm.nih.gov/pubmed/26051236",
							"http://www.ncbi.nlm.nih.gov/pubmed/23816963"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Non-Small Cell Lung Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/143"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/48",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/143"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/47",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/143"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/46",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/143"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/159",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/T790M",
				"source": "oncokb",
				"description": "FDA-approved biomarker and drug in this indication",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "http://oncokb.org/#/gene/EGFR/variant/T790M",
				"evidence_label": "A",
				"response_type": "NA",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/143",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/159"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/159",
						"type": "Predictive",
						"description": "1",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25923549",
							"http://www.ncbi.nlm.nih.gov/pubmed/27751847",
							"http://www.ncbi.nlm.nih.gov/pubmed/29151359"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Non-Small Cell Lung Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/159"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/100",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/159"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/309",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/T790M",
				"source": "oncokb",
				"description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved",
				"drug_labels": null,
				"variant_name": "T790M",
				"source_link": null,
				"evidence_label": null,
				"response_type": null,
				"evidence_level": null,
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/274",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/309"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/309",
						"type": "Predisposing",
						"description": "Gain-of-function",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15728811",
							"http://www.ncbi.nlm.nih.gov/pubmed/18227510",
							"http://www.ncbi.nlm.nih.gov/pubmed/15737014"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Oncogenic",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/309"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/645",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/642/summary#evidence",
				"source": "civic",
				"description": "Lung cancers can accumulate activating mutations in oncogenes such as EGFR. The common L858R EGFR mutation has been shown previously to be sensitive to small molecular tyrosine kinase inhibitors (ie. erlotinib). In response, tumors may accumulate an additional 'gatekeeper' mutation in EGFR, T790M. Authors show that T790M retain low affinity for gefitinib and that introduction of T790M in the presence of L858R mutant increases the ATP affinity of L858R and activates wild-type EGFR, thus showing that increased ATP affinity is the primary mode of resistance in tumors with T790M, though irreversible ATP inhibitors (ie. HKI-272) are able to overcome this resistance via covalent bonding.",
				"drug_labels": "GEFITINIB,497839-62-0",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/607",
						"source": "http://purl.obolibrary.org/obo/DOID_1324",
						"term": "lung cancer",
						"pheno_id": "DOID:1324",
						"family": "respiratory system cancer",
						"description": "lung cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/645"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/645",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18227510"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "642",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/645"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/456",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "497839-62-0",
						"envcontext_id": "CID10297043",
						"usan_stem": null,
						"description": "497839-62-0",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/645"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/455",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/645"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/646",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/646/summary#evidence",
				"source": "civic",
				"description": "In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC.",
				"drug_labels": "ROCILETINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/608",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/646"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/646",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25923550"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "646",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/646"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/457",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "ROCILETINIB",
						"envcontext_id": "57335384",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "ROCILETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/646"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/647",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/238/summary#evidence",
				"source": "civic",
				"description": "The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse.",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "A",
				"response_type": "resistant",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/609",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/647"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/647",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25668228"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "238",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/647"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/458",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/647"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/648",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/239/summary#evidence",
				"source": "civic",
				"description": "In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib.",
				"drug_labels": "GEFITINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/610",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/648"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/648",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15728811"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "239",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/648"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/459",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/648"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/649",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/240/summary#evidence",
				"source": "civic",
				"description": "In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance.",
				"drug_labels": "DACOMITINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/611",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/649"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/649",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21430269"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "240",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/649"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/460",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DACOMITINIB",
						"envcontext_id": "11511120",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "DACOMITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/649"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/650",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/277/summary#evidence",
				"source": "civic",
				"description": "In an NSCLC patient initially with L858R mutation, pemetrexed and cisplatin combination treatment was followed by erlotinib treatment. A slow progression developed which was found to be positive for L858R as well as T790M mutation which confers resistance to tyrosine kinase inhibitors. Due to slow tumor growth erlotinib was continued despite T790M, with re-addition of premetrexed, and this reduced tumor size and resulted in stable disease.",
				"drug_labels": "Erlotinib,Pemetrexed",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/612",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/650"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/650",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24636847"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "277",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/650"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/462",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Pemetrexed",
						"envcontext_id": "60843",
						"usan_stem": null,
						"description": "Pemetrexed",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/650"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/461",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/650"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/651",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/278/summary#evidence",
				"source": "civic",
				"description": "In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present.",
				"drug_labels": "Staurosporine",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/613",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/651"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/651",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24658966"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "278",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/651"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/463",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Staurosporine",
						"envcontext_id": "44259",
						"usan_stem": null,
						"description": "Staurosporine",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/651"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/652",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3801/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a Ba/F3 cell line expressing EGFR S752_I759del demonstrated increased sensitivity to erlotinib treatment (IC50=33nM), comparable to Ba/F3 cells expressing EGFR L858R (a known sensitizing mutation to EGFR tyrosine kinase inhibitors; IC50=16nM). Sensitivity was determined by assessing IL-3 independent cell survival.",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/614",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/652"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/652",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17877814"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3801",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/652"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/464",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/652"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/653",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3806/summary#evidence",
				"source": "civic",
				"description": "In a lung adenocarcinoma patient with EGFR E746_A751>A (a known erlotinib sensitizing mutation) and EGFR T790M co-mutation treated with erlotinib monotherapy, EGFR T790M was associated with disease progression. The patient was treated with erlotinib monotherapy and achieved a 10 month response rate, but subsequently developed disease progression upon emergence of the EGFR T790M mutation.",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/615",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/653"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/653",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17085664"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3806",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/653"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/465",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/653"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/654",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3807/summary#evidence",
				"source": "civic",
				"description": "In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/616",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/654"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/654",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15737014"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3807",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/654"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/466",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/654"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/655",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3808/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a NCI-H1975 cell line expressing EGFR L858R and EGFR T790M co-mutation, EGFR T790M was associated with reduced sensitivity to erlotinib treatment compared to QG56 cells expressing EGFR wild-type. Sensitivity was determined by assessing cell viability (mean IC50 of erlotinib for cells expressing EGFR L858R and EGFR T790M co-mutations was 4.3 M vs. 8.9 M for EGFR wild-type expressing cells).",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/617",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/655"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/655",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25853010"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3808",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/655"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/467",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/655"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/656",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/963/summary#evidence",
				"source": "civic",
				"description": "Cell line, xenograft, and transgenic models were used to establish Osimertinib as an inhibitor of both EGFR mutation sensitizing (L858M, del exon 19) and T790M resistance mutants. Preclinically, the drug inhibits signaling pathways and cellular growth in both EGFRm(+) and EGFRm(+)/T790M(+) mutant cell lines in vitro, with lower activity against wild-type EGFR lines. Sustained tumor regression was observed in EGFR-mutant tumor xenograft and transgenic models. Treatment of 2 patients with advanced EGFRm(+) T790M(+) NSCLC was reported as proof of principle.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/618",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/656"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/656",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24893891"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "963",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/656"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/468",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/656"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/657",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/965/summary#evidence",
				"source": "civic",
				"description": "This phase I/II trial (NCT01802632) involved 253 non-small cell lung cancer patients with activating EGFR mutations, who had progressed on first generation tyrosine kinase inhibitor treatment, and were subsequently treated with Osimertinib (AZD9291). The overall objective tumor response rate was 51%. Among 127 patients with EGFR T790M who could be evaluated for response, the response rate was 61% (95% CI, 52 to 70). In contrast, among 61 patients without EGFR T790M, the response rate was 21% (95% CI, 12 to 34). The median progression-free survival was 9.6 months in EGFR T790M-positive patients and 2.8 months in EGFR T790M-negative patients.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/619",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/657"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/657",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25923549"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "965",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/657"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/469",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/657"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/658",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/966/summary#evidence",
				"source": "civic",
				"description": "This study summarized 9 EGFR-mutant patients from two clinical trials involving rociletinib (NCT01526928) and subsequent osimertinib (NCT01802632). 8 were T790M-positive prior to treatment with osimertinib. 6 transitioned directly from rociletinib to osimertinib. 3 patients achieved PR and 4 achieved SD. The median PFS was 208 days (95% CI, 41-208 days). Among 6 patients who transitioned directly from rociletinib to osimertinib all derived clinical benefit from osimertinib with either prolonged SD or PR.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/620",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/658"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/658",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26720284"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "966",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/658"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/470",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/658"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/659",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/967/summary#evidence",
				"source": "civic",
				"description": "For cell harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
				"drug_labels": "OSIMERTINIB,ROCILETINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/621",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/659"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/659",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26515464"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "967",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/659"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/472",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "ROCILETINIB",
						"envcontext_id": "57335384",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "ROCILETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/659"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/471",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/659"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/660",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3809/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R and T790M co-mutation demonstrated resistance to erlotinib treatment, compared to MCF-7 cells expressing a known erlotinib sensitizing mutation (EGFR L858R). Sensitivity was determined by assessing YFP signal-EGFR relocation.",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/622",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/660"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/660",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21132006"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3809",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/660"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/473",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/660"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/661",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3810/summary#evidence",
				"source": "civic",
				"description": "Experimental - EGFR T790M mutation has been associated with resistance to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study, Ba/F3 cells stably expressing EGFR T790M demonstrated  resistance to gefitinib and erlotinib and the tool construct AEE788. These cells had very high IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib>2000, Erlotinib>2000, AEE788>2000), indicating resitance to all three inhibitors.",
				"drug_labels": "Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": null,
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/623",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/661"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/661",
						"type": "Predictive",
						"description": null,
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19147750"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3810",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/661"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/474",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/661"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/662",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/3812/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, the recombinant EGFR T790M mutation kinase was associated with reduced sensitivity to bosutinib(IC50: 491nM), as compared to wild-type EGFR kinase (IC50: 53nM). Resistance was assessed by analyzing kinase inhibition.",
				"drug_labels": "BOSUTINIB MONOHYDRATE",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/624",
						"source": "http://purl.obolibrary.org/obo/DOID_8552",
						"term": "chronic myeloid leukemia",
						"pheno_id": "DOID:8552",
						"family": "leukemia",
						"description": "chronic myeloid leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/662"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/662",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19039322"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3812",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/662"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/475",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "BOSUTINIB MONOHYDRATE",
						"envcontext_id": "5328940",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "BOSUTINIB MONOHYDRATE",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/662"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/663",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/1391/summary#evidence",
				"source": "civic",
				"description": "155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). 98 patients were found to have developed EGFR T790M mutations.",
				"drug_labels": "GEFITINIB,Erlotinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/625",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/663"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/663",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23470965"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1391",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/663"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/477",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/663"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/476",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/663"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/664",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/762/summary#evidence",
				"source": "civic",
				"description": "CO-1686 (Rociletinib) more effectively induced apoptosis in EGFR mutated (T790M and others) NSCLC cell lines than those harboring wildtype EGFR. CO-1686 also more effectively reduced tumor volume of mouse xenografts harboring the T790M than those with wildtype EGFR.",
				"drug_labels": "ROCILETINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/626",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/664"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/664",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24065731"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "762",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/664"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/478",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "ROCILETINIB",
						"envcontext_id": "57335384",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "ROCILETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/664"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/665",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/1592/summary#evidence",
				"source": "civic",
				"description": "Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "A",
				"response_type": "Sensitivity/Response",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/627",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/665"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/665",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26729184"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1592",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/665"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/479",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/665"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/666",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/1667/summary#evidence",
				"source": "civic",
				"description": "48 tumor samples from 41 patients with EGFR mutant lung adenocarcinoma that were resistant to tyrosine kinase inhibition underwent next generation sequencing (NGS failed in 5 samples leading to a remaining 43 specimens from 39 patients). The prevalence of various mutations post-treatment was analyzed. 79%, or 31 out of the 39 patients,  had the T790M EGFR mutation present, indicating its importance in the development of resistance.",
				"drug_labels": "GEFITINIB,Erlotinib,AFATINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/628",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/666"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/666",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27304188"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1667",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/666"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/482",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/666"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/481",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/666"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/480",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/666"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/667",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/1397/summary#evidence",
				"source": "civic",
				"description": "Case report of a patient with stage IV lung adenocarcinoma and a 15base pair deletion in EGFR exon 19. Partial response with erlotinib was achieved for 15 months after initial chemotherapy. After further progression, rebiopsy additionally identified the EGFR T790M mutation and the patient received several cycles of chemotherapy and targeted therapy including afatinib, cetuximab, erlotinib, AZD9291. She was treated with AZD9291 for 9 months until disease progression.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/629",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/667"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/667",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26181354"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1397",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/667"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/483",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/667"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/668",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/1863/summary#evidence",
				"source": "civic",
				"description": "Patients with advanced NSCLC and acquired resistance to EGFR TKI (gefitinib or erlotinib) were analyzed for T790M mutations.  Of the 70 patients analyzed, 36 (51%) had the T790M mutation and 34 (49%) were T790M-negative.  There was no significant difference in the median post-progression or overall survival between patients with T790M mutation and without T790M mutation for initial TKI treatment.  However, subsequent treatment with afatinib showed partial response in six patients where 1/21(5%) were in the T790M-positive group and 5/13 (38%) were in the T790M-negative group (P=0.01).",
				"drug_labels": "AFATINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/630",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/668"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/668",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24035188"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1863",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/668"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/484",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/668"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/669",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/1867/summary#evidence",
				"source": "civic",
				"description": "Randomized, international, open-label, phase 3 trial (NCT02151981) in 419 patients with T790M-positive advanced NSCLC and disease progression after first-line EGFR-TKI therapy. Patients were randomized, in a 2:1 ratio, to oral osimertinib or chemotherapy (pemetrexed plus either carboplatin or cisplatin every 3 weeks for up to six cycles, maintenance pemetrexed was allowed). Primary end point was PFS, which was significantly longer with osimertinib than with chemotherapy (10.1 months vs. 4.4 months; HR 0.30; 95% CI: 0.23 to 0.41; P<0.001). Objective response rate was significantly better with osimertinib (71%; 95% CI, 65 to 76) than with chemotherapy (31%; 95% CI, 24 to 40) (odds ratio for objective response, 5.39; 95% CI, 3.47 to 8.48; P<0.001).",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "A",
				"response_type": "Sensitivity/Response",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/631",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/669"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/669",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27959700"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1867",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/669"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/485",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/669"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/670",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2157/summary#evidence",
				"source": "civic",
				"description": "In a lung adenocarcinoma patient harboring an EGFR E746_A750 mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with gefitinib and achieved a partial response, but subsequently tumor progression occurred; however, osimertinib treatment resulted a favorable tumor response with the extinguishment of the EGFR T790M mutation. In a stage IV lung adenocarcinoma patient harboring an EGFR L858R mutation and an acquired EGFR T790M co-mutation, EGFR T790M was associated with sensitivity to osimertinib monotherapy. Prior to the development of the EGFR T790M mutation, the patient was treated with erlotinib, followed by gefitinib for 12 months and achieved stable disease, but subsequently metastasis occurred; the EGFR T790M was then identified and subsequent 10 month treatment with osimertinib monotherapy resulted in a 45% disease regression.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/632",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/670"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/670",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26269204"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2157",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/670"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/486",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/670"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/671",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2158/summary#evidence",
				"source": "civic",
				"description": "In a study of 6 patients with progressive non-small cell lung cancer during gefitinib or erlotinib therapy,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 2 patients acquired a new EGFR-T790M mutation.",
				"drug_labels": "GEFITINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/633",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/671"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/671",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15737014"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2158",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/671"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/487",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/671"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/672",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2159/summary#evidence",
				"source": "civic",
				"description": "In a study of 14 patients with progressive non-small cell lung cancer during gefitinib,  comparison of DNA sequences from the original diagnostic biopsy specimen and the second biopsy specimen demonstrated that 7 patients acquired a new EGFR-T790M mutation.",
				"drug_labels": "GEFITINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/634",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/672"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/672",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17020982"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2159",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/672"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/488",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/672"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/673",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2160/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated a reduced response to lapatinib (IC50: >4000nM vs. 534nM) compared to wildtype EGFR cells. Similarly, NIH-3T3 ectopically expression EGFR-L858R/T790M showed reduced sensistivity to lapatinib compared to EGFR wt or L585R mutant cells. These results were further confirmed in a Ba/F3 cell line model",
				"drug_labels": "Lapatinib",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/635",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/673"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/673",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2160",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/673"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/489",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Lapatinib",
						"envcontext_id": "208908",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Lapatinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/673"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/674",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2161/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. PF00299804 inhibited the growth of Ba/F3 cell lines containing the EFGR T790M resistance mutation as well as H1975 and H3255 cell lines that contain both EGFR L858R and T790M mutations and H820 containing an EGFR exon 19 deletion (Del 747_L751, Ins S) and a T790M mutation. All three cell lines were resistant to gefitinib in vitro, but sensitive to PF00299804 (IC50 <1 mol/L for all three cell lines).",
				"drug_labels": "DACOMITINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/636",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/674"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/674",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18089823"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2161",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/674"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/490",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "DACOMITINIB",
						"envcontext_id": "CHEMBL2105719",
						"usan_stem": null,
						"description": "DACOMITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/674"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/675",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2162/summary#evidence",
				"source": "civic",
				"description": "The NSCLC cell line NCI-H1975 carrying the EGFR T790M mutation was resistant to erlotinib but showed increased sensitivity to HKI-272 (neratinib, IC50: 0.29 mol/L).\nIn an in vitro study Ba/F3 cells transfected with either EGFR-L858R or EGFR-L858R/T790M were used to assay cell growth. Ba/F3 cells require IL-3 in order to proliferate, but cells transfected with an activated oncogene are IL-3 independent. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to neratinib (IC50: 0.185umol/L vs. >10umol/L) compared to the same cells treated with erlotinib.",
				"drug_labels": "NERATINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/637",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/675"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/675",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16818618"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2162",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/675"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/491",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "NERATINIB",
						"envcontext_id": "9915743",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "NERATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/675"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/676",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2163/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (IC50: 99nM vs. >4000nM) compared to the same cells treated with erlotinib. In an in vivo mouse xenograft study, the growth of cells with an EGFR-L858R/T790M mutation were more sensitive to treatment of afatinib (concentration: 15-20mg/kg) (median tumor volume = 75-150mm^3 vs. 1000mm^3), compared to reversible TKI lapatinib-treated xenografts. However, no complete responses were observed with afatinib alone.",
				"drug_labels": "AFATINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/638",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/676"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/676",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2163",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/676"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/492",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/676"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/677",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2164/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using purified EGFR protein, kinase activity was assayed and compared for wildtype EGFR, EGFR-T790M and EGFR-T790M/L858R using both reversible and irreversible TKI drugs. EFGR proteins with T790M or T790M/L858R mutations were more sensitive to afatinib treatment (IC50: 9.8nM and 24nM, respectively vs. IC50: >1000nM and >1000nM, respectively) compared to treatment with erlotinib or lapatinib treatment. In an in vitro study using NCI-H358 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to afatinib (GI50: 42.0nM vs. >1000nM) compared to the same cells treated with erlotinib. However, IC50s were intermediate compared to a more potent pan-HER inhibitor.",
				"drug_labels": "AFATINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/639",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/677"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/677",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21732342"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2164",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/677"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/493",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/677"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/678",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/2165/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H1975 cells (EGFR-L858R/T790M), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R/T790M mutation demonstrated an improved response to canertinib (IC50: 101nM vs. >4000nM) compared to the same cells treated with erlotinib. IC50 values of canertinib were comparable to afatinib.",
				"drug_labels": "CANERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/640",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/678"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/678",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2165",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/678"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/494",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "CANERTINIB",
						"envcontext_id": "156414",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "CANERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/678"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/679",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/4836/summary#evidence",
				"source": "civic",
				"description": "Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR-TKI resistance to Osimertinib. In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibodies Ceutximab or Panitumumab because of the decrease of surface and total EGFR expression. Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR.",
				"drug_labels": "BRIGATINIB,PANITUMUMAB,CETUXIMAB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/641",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/679"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/679",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/28287083"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4836",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/679"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/497",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/679"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/496",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/679"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/495",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "BRIGATINIB",
						"envcontext_id": "68165256",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "BRIGATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/679"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/680",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/6006/summary#evidence",
				"source": "civic",
				"description": "Patients with recurrent pancreatic adenocarcinoma was treated with gemcitabine + nab-paclitaxel, FOLFIRINOX and docetaxel + irinotecan. After failure of these treatment, a tumor specimen from the pancreaticoduodenectomy was analysed, which revealed an activating mutation in exon 19 (L747_P753>S) of EGFR. Mutations were also detected in CDKN2A, TP53, and amplifications of PRKCI and TERC. He began erlotinib at 150mg daily. CT imaging  revealed a partial response by RECIST at 8, 24 and 32 weeks after starting erlotinib. At 40 weeks CT imaging revealed unequivocal disease progression. After disease progression to erlotinib, a repeat liver biopsy revealed an EGFR T790M mutation. He began treatment with osimertinib at 80mg daily. After 8 weeks of this treatment CT imaging revealed unequivocal disease progression.",
				"drug_labels": "OSIMERTINIB",
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/642",
						"source": "http://purl.obolibrary.org/obo/DOID_4074",
						"term": "pancreatic adenocarcinoma",
						"pheno_id": "DOID:4074",
						"family": "pancreatic cancer",
						"description": "pancreatic adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/680"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/680",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/28874593"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6006",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/680"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/498",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/680"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/681",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/370/summary#evidence",
				"source": "civic",
				"description": "Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.",
				"drug_labels": null,
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/643",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/681"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/681",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24729716"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "370",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/681"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/682",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/130",
					"name": "T790M",
					"description": "EGFR T790M",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55249071,
					"end_pos": 55249071,
					"ref": "C",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.55249071C>T",
					"hgvs_c": "NM_005228.3:c.2369C>T",
					"hgvs_p": "NP_005219.2:p.Thr790Met",
					"dbsnp_ids": [
						"121434569"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/34/summary/evidence/369/summary#evidence",
				"source": "civic",
				"description": "In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation.",
				"drug_labels": null,
				"variant_name": "T790M",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/34/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/644",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/682"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/682",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24623981"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "369",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/682"
					}
				],
				"environmentalcontext_set": [

				]
			}
		],
		"name": "T790M",
		"description": "EGFR T790M",
		"biomarker_type": "missense_variant",
		"so_hierarchy": [
			"SO:0001060",
			"SO:0001537",
			"SO:0001878",
			"SO:0001564",
			"SO:0001576",
			"SO:0001791",
			"SO:0001580",
			"SO:0001818",
			"SO:0001650",
			"SO:0001992"
		],
		"soid": "SO:0001583",
		"so_name": "missense_variant",
		"reference_name": "GRCh37",
		"refseq": "NM_005228.3",
		"isoform": "ENST00000275493",
		"chromosome": "7",
		"start_pos": 55249071,
		"end_pos": 55249071,
		"ref": "C",
		"alt": "T",
		"hgvs_g": "NC_000007.13:g.55249071C>T",
		"hgvs_c": "NM_005228.3:c.2369C>T",
		"hgvs_p": "NP_005219.2:p.Thr790Met",
		"dbsnp_ids": [
			"121434569"
		],
		"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55249071C>T?assembly=hg19",
		"gene": {
			"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
			"entrez_id": 1956,
			"ensembl_gene_id": "ENSG00000146648",
			"symbol": "EGFR",
			"uniprot_ids": [
				"P00533"
			],
			"location": "7p11.2",
			"sources": {
				"civic": null,
				"oncokb": null
			}
		}
	},
	"142": {
		"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
		"sources": [
			"civic",
			"oncokb"
		],
		"association_set": [
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/L858R",
				"source": "oncokb",
				"description": "FDA-approved biomarker and drug in this indication",
				"drug_labels": "Erlotinib,AFATINIB,OSIMERTINIB,DACOMITINIB,GEFITINIB",
				"variant_name": "L858R",
				"source_link": "http://oncokb.org/#/gene/EGFR/variant/L858R",
				"evidence_label": "A",
				"response_type": "NA",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/139",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/155",
						"type": "Predictive",
						"description": "1",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/28958502",
							"http://www.ncbi.nlm.nih.gov/pubmed/23816960",
							"http://www.ncbi.nlm.nih.gov/pubmed/20022809",
							"http://www.ncbi.nlm.nih.gov/pubmed/21670455",
							"http://www.ncbi.nlm.nih.gov/pubmed/29151359",
							"http://www.ncbi.nlm.nih.gov/pubmed/22452895",
							"http://www.ncbi.nlm.nih.gov/pubmed/25589191",
							"http://www.ncbi.nlm.nih.gov/pubmed/22285168",
							"http://www.ncbi.nlm.nih.gov/pubmed/29864379",
							"http://www.ncbi.nlm.nih.gov/pubmed/19692680",
							"http://www.ncbi.nlm.nih.gov/pubmed/27987585",
							"http://www.ncbi.nlm.nih.gov/pubmed/22370314",
							"http://www.ncbi.nlm.nih.gov/pubmed/20573926"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Non-Small Cell Lung Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/90",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/89",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DACOMITINIB",
						"envcontext_id": "11511120",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "DACOMITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/88",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "OSIMERTINIB",
						"envcontext_id": "71496458",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "OSIMERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/87",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/86",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/155"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/276",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "http://oncokb.org/#/gene/EGFR/variant/L858R",
				"source": "oncokb",
				"description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved",
				"drug_labels": null,
				"variant_name": "L858R",
				"source_link": null,
				"evidence_label": null,
				"response_type": null,
				"evidence_level": null,
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/247",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/276"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/276",
						"type": "Predisposing",
						"description": "Gain-of-function",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15329413",
							"http://www.ncbi.nlm.nih.gov/pubmed/15118073",
							"http://www.ncbi.nlm.nih.gov/pubmed/15118125"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "EGFR-Oncogenic",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/276"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/506",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/229/summary#evidence",
				"source": "civic",
				"description": "There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).",
				"drug_labels": "GEFITINIB,Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/468",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/506"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/506",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24736073"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "229",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/506"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/307",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/506"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/306",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/506"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/507",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/276/summary#evidence",
				"source": "civic",
				"description": "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/469",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/507"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/507",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15118125"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "276",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/507"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/308",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/507"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/508",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/879/summary#evidence",
				"source": "civic",
				"description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/470",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/508"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/508",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23816960"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "879",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/508"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/309",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/508"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/509",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/883/summary#evidence",
				"source": "civic",
				"description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/471",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/509"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/509",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22452895"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "883",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/509"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/310",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/509"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/510",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/885/summary#evidence",
				"source": "civic",
				"description": "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/472",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/510"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/510",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22285168"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "885",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/510"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/311",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/510"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/511",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/968/summary#evidence",
				"source": "civic",
				"description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/473",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/511"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/511",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26515464"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "968",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/511"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/312",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/511"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/512",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/982/summary#evidence",
				"source": "civic",
				"description": "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/474",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/512"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/512",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24439929"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "982",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/512"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/313",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/512"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/513",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/275/summary#evidence",
				"source": "civic",
				"description": "In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.",
				"drug_labels": "GEFITINIB,Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/475",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/513"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/513",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24457318"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "275",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/513"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/315",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/513"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/314",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/513"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/514",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/1665/summary#evidence",
				"source": "civic",
				"description": "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were  treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR(median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for TTF (HR = 0.1030; P = .0004).",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/476",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/514"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/514",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18509184"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1665",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/514"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/316",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/514"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/515",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2621/summary#evidence",
				"source": "civic",
				"description": "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/477",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/515"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/515",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20038723"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2621",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/515"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/317",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/515"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/516",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2623/summary#evidence",
				"source": "civic",
				"description": "In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, HR: 0.30, 95% CI: 0.22-0.41, P<0.001), compared to patients treated with carboplatin and paclitaxel combination therapy. The frequency of mutation of exon 19 deletion and L858R was 25.2% (58/230) and 21.3% (49/230), respectively.",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/478",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/516"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/516",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20573926"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2623",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/516"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/318",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/516"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/517",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2624/summary#evidence",
				"source": "civic",
				"description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/479",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/517"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/517",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15329413"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2624",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/517"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/319",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/517"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/518",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2625/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using PC9 cells (EGFR exon 19 deletion), inhibition of cell viability was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 23.0 nmol/L vs 200.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/480",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/518"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/518",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24893891"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2625",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/518"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/320",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/518"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/519",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2626/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.",
				"drug_labels": "Lapatinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/481",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/519"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/519",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2626",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/519"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/321",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Lapatinib",
						"envcontext_id": "208908",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Lapatinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/519"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/520",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2627/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to PF 00299804  (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).",
				"drug_labels": "DACOMITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/482",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/520"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/520",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18089823"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2627",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/520"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/322",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "DACOMITINIB",
						"envcontext_id": "CHEMBL2105719",
						"usan_stem": null,
						"description": "DACOMITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/520"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/521",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2628/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1781 cells (EGFR wild-type) and NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to neratinib (IC50: 0.0049umol/L vs. 0.085umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug erlotinib (IC50: 0.031umol/L vs. wildtype >1umol/L).",
				"drug_labels": "NERATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/483",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/521"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/521",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16818618"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2628",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/521"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/323",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "NERATINIB",
						"envcontext_id": "9915743",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "NERATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/521"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/522",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2629/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/484",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/522"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/522",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2629",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/522"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/324",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/522"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/523",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2630/summary#evidence",
				"source": "civic",
				"description": "In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/485",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/523"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/523",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22452896"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2630",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/523"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/325",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/523"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/524",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2631/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.",
				"drug_labels": "CANERTINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/486",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/524"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/524",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2631",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/524"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/326",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "CANERTINIB",
						"envcontext_id": "156414",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "CANERTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/524"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/525",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2633/summary#evidence",
				"source": "civic",
				"description": "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib  (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
				"drug_labels": "Durvalumab",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": null,
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/487",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/525"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/525",
						"type": "Predictive",
						"description": null,
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24893891"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2633",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/525"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/327",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/substance",
						"term": "Durvalumab",
						"envcontext_id": "SID249565666",
						"usan_stem": null,
						"description": "Durvalumab",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/525"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/526",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2634/summary#evidence",
				"source": "civic",
				"description": "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/488",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/526"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/526",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22370314"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2634",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/526"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/328",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/526"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/527",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4265/summary#evidence",
				"source": "civic",
				"description": "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/489",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/527"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/527",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17877814"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4265",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/527"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/329",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/527"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/528",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4284/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/490",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/528"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/528",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18408761"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4284",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/528"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/330",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/528"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/529",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4285/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/491",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/529"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/529",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21132006"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4285",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/529"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/331",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/529"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/530",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4286/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/492",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/530"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/530",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24353160"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4286",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/530"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/332",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/530"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/531",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4287/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/493",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/531"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/531",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27612423"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4287",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/531"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/333",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/531"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/532",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4288/summary#evidence",
				"source": "civic",
				"description": "In a non-small cell lung cancer patient with an EGFR L858R mutation, EGFR L858R was reported to be refractory to 61-day crizotinib treatment.",
				"drug_labels": "CRIZOTINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/494",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/532"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/532",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22235099"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4288",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/532"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/334",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "CRIZOTINIB",
						"envcontext_id": "11626560",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "CRIZOTINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/532"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/533",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4290/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 46 Caucasian, advanced lung adenocarcinoma patients, a patient harboring EGFR L858R mutation was associated with resistance to erlotinib treatment; the patient survived 3.9 months, as compared to the overall 24 months median overall survival of the other patients who were not resistant to erlotinib treatment.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/495",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/533"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/533",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27032107"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4290",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/533"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/335",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/533"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/534",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4291/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/496",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/534"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/534",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27102076"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4291",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/534"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/336",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/534"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/535",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4292/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to cetuximab treatment. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.",
				"drug_labels": "CETUXIMAB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/497",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/535"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/535",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27102076"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4292",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/535"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/337",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/535"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/536",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4293/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated an sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": null,
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/498",
						"source": "http://purl.obolibrary.org/obo/DOID_5409",
						"term": "lung small cell carcinoma",
						"pheno_id": "DOID:5409",
						"family": "lung cancer",
						"description": "lung small cell carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/536"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/536",
						"type": "Predictive",
						"description": null,
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24893891"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4293",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/536"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/338",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/536"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/537",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4294/summary#evidence",
				"source": "civic",
				"description": "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib. In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8.0-11.0 nmol/L vs 108.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
				"drug_labels": "CETUXIMAB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": null,
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/499",
						"source": "http://purl.obolibrary.org/obo/DOID_2531",
						"term": "hematologic cancer",
						"pheno_id": "DOID:2531",
						"family": "organ system cancer",
						"description": "hematologic cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/537"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/537",
						"type": "Predictive",
						"description": null,
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24893891"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4294",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/537"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/339",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/537"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/538",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4295/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/500",
						"source": "http://purl.obolibrary.org/obo/DOID_3070",
						"term": "malignant glioma",
						"pheno_id": "DOID:3070",
						"family": "cell type cancer",
						"description": "malignant glioma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/538"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/538",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17177598"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4295",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/538"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/340",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/538"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/539",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2994/summary#evidence",
				"source": "civic",
				"description": "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "A",
				"response_type": "Sensitivity/Response",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/501",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/539"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/539",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24868098"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2994",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/539"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/341",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/539"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/540",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2997/summary#evidence",
				"source": "civic",
				"description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
				"drug_labels": "AFATINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "A",
				"response_type": "Sensitivity/Response",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/502",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/540"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/540",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23982599"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2997",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/540"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/342",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "AFATINIB",
						"envcontext_id": "10184653",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "AFATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/540"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/541",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/4860/summary#evidence",
				"source": "civic",
				"description": "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.",
				"drug_labels": "DACOMITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/503",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/541"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/541",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26768165"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4860",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/541"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/343",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DACOMITINIB",
						"envcontext_id": "11511120",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "DACOMITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/541"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/542",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/2632/summary#evidence",
				"source": "civic",
				"description": "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/504",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/542"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/542",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15329413"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2632",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/542"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/344",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/542"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/543",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/3811/summary#evidence",
				"source": "civic",
				"description": "EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.",
				"drug_labels": "GEFITINIB,Erlotinib,497839-62-0",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/505",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/543"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/543",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19147750"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3811",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/543"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/347",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "497839-62-0",
						"envcontext_id": "CID10297043",
						"usan_stem": null,
						"description": "497839-62-0",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/543"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/346",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/543"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/345",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/543"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/544",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/5922/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR \n expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.",
				"drug_labels": "Erlotinib",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/506",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/544"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/544",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20942962"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5922",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/544"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/348",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Erlotinib",
						"envcontext_id": "176870",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "Erlotinib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/544"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/545",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/6183/summary#evidence",
				"source": "civic",
				"description": "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).",
				"drug_labels": "GEFITINIB",
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Reduced Sensitivity",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/507",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/545"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/545",
						"type": "Predictive",
						"description": "Reduced Sensitivity",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27022112"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6183",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/545"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/349",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/545"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/546",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
					"entrez_id": 1956,
					"ensembl_gene_id": "ENSG00000146648",
					"symbol": "EGFR",
					"uniprot_ids": [
						"P00533"
					],
					"location": "7p11.2",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/142",
					"name": "L858R",
					"description": "EGFR L858R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_005228.3",
					"isoform": "ENST00000275493",
					"chromosome": "7",
					"start_pos": 55259515,
					"end_pos": 55259515,
					"ref": "T",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.55259515T>G",
					"hgvs_c": "NM_005228.3:c.2573T>G",
					"hgvs_p": "NP_005219.2:p.Leu858Arg",
					"dbsnp_ids": [
						"121434568"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2"
				},
				"source_url": "https://civicdb.org/events/genes/19/summary/variants/33/summary/evidence/347/summary#evidence",
				"source": "civic",
				"description": "Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.",
				"drug_labels": null,
				"variant_name": "L858R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/19/summary/variants/33/summary",
				"evidence_label": "B",
				"response_type": "Better Outcome",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/508",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/546"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/546",
						"type": "Prognostic",
						"description": "Better Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24662454"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "347",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/546"
					}
				],
				"environmentalcontext_set": [

				]
			}
		],
		"name": "L858R",
		"description": "EGFR L858R",
		"biomarker_type": "missense_variant",
		"so_hierarchy": [
			"SO:0001060",
			"SO:0001537",
			"SO:0001878",
			"SO:0001564",
			"SO:0001576",
			"SO:0001791",
			"SO:0001580",
			"SO:0001818",
			"SO:0001650",
			"SO:0001992"
		],
		"soid": "SO:0001583",
		"so_name": "missense_variant",
		"reference_name": "GRCh37",
		"refseq": "NM_005228.3",
		"isoform": "ENST00000275493",
		"chromosome": "7",
		"start_pos": 55259515,
		"end_pos": 55259515,
		"ref": "T",
		"alt": "G",
		"hgvs_g": "NC_000007.13:g.55259515T>G",
		"hgvs_c": "NM_005228.3:c.2573T>G",
		"hgvs_p": "NP_005219.2:p.Leu858Arg",
		"dbsnp_ids": [
			"121434568"
		],
		"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.55259515T>G?assembly=hg19",
		"gene": {
			"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/2",
			"entrez_id": 1956,
			"ensembl_gene_id": "ENSG00000146648",
			"symbol": "EGFR",
			"uniprot_ids": [
				"P00533"
			],
			"location": "7p11.2",
			"sources": {
				"civic": null,
				"oncokb": null
			}
		}
	},
	"56": {
		"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/56",
		"sources": [
			"civic",
			"oncokb"
		],
		"association_set": [
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/65",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/56",
					"name": "G596R",
					"description": "BRAF G596R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453149,
					"end_pos": 140453149,
					"ref": "C",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.140453149C>G",
					"hgvs_c": "NM_004333.4:c.1786G>C",
					"hgvs_p": "NP_004324.2:p.Gly596Arg",
					"dbsnp_ids": [
						"121913361"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453149C>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "http://oncokb.org/#/gene/BRAF/variant/G596R",
				"source": "oncokb",
				"description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved",
				"drug_labels": null,
				"variant_name": "G596R",
				"source_link": null,
				"evidence_label": null,
				"response_type": null,
				"evidence_level": null,
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/61",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/65"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/65",
						"type": "Predisposing",
						"description": "Gain-of-function",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/14678966",
							"http://www.ncbi.nlm.nih.gov/pubmed/26498038",
							"http://www.ncbi.nlm.nih.gov/pubmed/16364920",
							"http://www.ncbi.nlm.nih.gov/pubmed/28783719",
							"http://www.ncbi.nlm.nih.gov/pubmed/15035987"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "BRAF-Oncogenic",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/65"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/969",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/56",
					"name": "G596R",
					"description": "BRAF G596R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453149,
					"end_pos": 140453149,
					"ref": "C",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.140453149C>G",
					"hgvs_c": "NM_004333.4:c.1786G>C",
					"hgvs_p": "NP_004324.2:p.Gly596Arg",
					"dbsnp_ids": [
						"121913361"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453149C>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/1627/summary/evidence/5969/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Nonresponding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "G596R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/1627/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/931",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/969"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/969",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5969",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/969"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/842",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/969"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/970",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/56",
					"name": "G596R",
					"description": "BRAF G596R",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453149,
					"end_pos": 140453149,
					"ref": "C",
					"alt": "G",
					"hgvs_g": "NC_000007.13:g.140453149C>G",
					"hgvs_c": "NM_004333.4:c.1786G>C",
					"hgvs_p": "NP_004324.2:p.Gly596Arg",
					"dbsnp_ids": [
						"121913361"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453149C>G?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/1627/summary/evidence/4729/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated reduced sensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing mutation). Resistance was determined by assessing cellular proliferation.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "G596R",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/1627/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/932",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/970"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/970",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22180495"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "4729",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/970"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/843",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/970"
					}
				]
			}
		],
		"name": "G596R",
		"description": "BRAF G596R",
		"biomarker_type": "missense_variant",
		"so_hierarchy": [
			"SO:0001060",
			"SO:0001537",
			"SO:0001878",
			"SO:0001564",
			"SO:0001576",
			"SO:0001791",
			"SO:0001580",
			"SO:0001818",
			"SO:0001650",
			"SO:0001992"
		],
		"soid": "SO:0001583",
		"so_name": "missense_variant",
		"reference_name": "GRCh37",
		"refseq": "NM_004333.4",
		"isoform": "ENST00000288602",
		"chromosome": "7",
		"start_pos": 140453149,
		"end_pos": 140453149,
		"ref": "C",
		"alt": "G",
		"hgvs_g": "NC_000007.13:g.140453149C>G",
		"hgvs_c": "NM_004333.4:c.1786G>C",
		"hgvs_p": "NP_004324.2:p.Gly596Arg",
		"dbsnp_ids": [
			"121913361"
		],
		"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453149C>G?assembly=hg19",
		"gene": {
			"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
			"entrez_id": 673,
			"ensembl_gene_id": "ENSG00000157764",
			"symbol": "BRAF",
			"uniprot_ids": [
				"P15056"
			],
			"location": "7q34",
			"sources": {
				"civic": null,
				"oncokb": null
			}
		}
	},
	"1": {
		"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
		"sources": [
			"civic",
			"oncokb"
		],
		"association_set": [
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/130",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"source": "oncokb",
				"description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": null,
				"evidence_label": null,
				"response_type": null,
				"evidence_level": null,
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/117",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/130"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/130",
						"type": "Predisposing",
						"description": "Gain-of-function",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25417114",
							"http://www.ncbi.nlm.nih.gov/pubmed/20179705",
							"http://www.ncbi.nlm.nih.gov/pubmed/23833300",
							"http://www.ncbi.nlm.nih.gov/pubmed/26091043",
							"http://www.ncbi.nlm.nih.gov/pubmed/26343582",
							"http://www.ncbi.nlm.nih.gov/pubmed/12068308",
							"http://www.ncbi.nlm.nih.gov/pubmed/25079552",
							"http://www.ncbi.nlm.nih.gov/pubmed/28783719",
							"http://www.ncbi.nlm.nih.gov/pubmed/19251651",
							"http://www.ncbi.nlm.nih.gov/pubmed/15035987"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "BRAF-Oncogenic",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/130"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/787",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/90/summary#evidence",
				"source": "civic",
				"description": "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/749",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/787"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/787",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24576830"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "90",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/787"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/631",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/787"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/788",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/82/summary#evidence",
				"source": "civic",
				"description": "BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.",
				"drug_labels": "DACARBAZINE,TEMOZOLOMIDE",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "N/A",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/750",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/788"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/788",
						"type": "Predictive",
						"description": "N/A",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24586605"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "82",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/788"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/633",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TEMOZOLOMIDE",
						"envcontext_id": "5394",
						"usan_stem": null,
						"description": "TEMOZOLOMIDE",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/788"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/632",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "DACARBAZINE",
						"envcontext_id": "CHEMBL476",
						"usan_stem": null,
						"description": "DACARBAZINE",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/788"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/789",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/89/summary#evidence",
				"source": "civic",
				"description": "Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.",
				"drug_labels": "Sorafenib,PANITUMUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/751",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/789"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/789",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19001320"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "89",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/789"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/635",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/789"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/634",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Sorafenib",
						"envcontext_id": "216239",
						"usan_stem": "raf kinase inhibitors",
						"description": "Sorafenib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/789"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/790",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/91/summary#evidence",
				"source": "civic",
				"description": "In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/752",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/790"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/790",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23524406"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "91",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/790"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/636",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/790"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/791",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/95/summary#evidence",
				"source": "civic",
				"description": "Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/753",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/791"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/791",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24583796"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "95",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/791"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/638",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/791"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/637",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/791"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/792",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/96/summary#evidence",
				"source": "civic",
				"description": "Combined MEK inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.",
				"drug_labels": "PLX-4720,GDC-0941",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/754",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/792"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/792",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23845441"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "96",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/792"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/640",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GDC-0941",
						"envcontext_id": "CID17755052",
						"usan_stem": null,
						"description": "GDC-0941",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/792"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/639",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "PLX-4720",
						"envcontext_id": "CID24180719",
						"usan_stem": null,
						"description": "PLX-4720",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/792"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/793",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/97/summary#evidence",
				"source": "civic",
				"description": "Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.",
				"drug_labels": "PLX-4720,Nutlin",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/755",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/793"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/793",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23812671"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "97",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/793"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/642",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Nutlin",
						"envcontext_id": "71582991",
						"usan_stem": null,
						"description": "Nutlin",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/793"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/641",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "PLX-4720",
						"envcontext_id": "CID24180719",
						"usan_stem": null,
						"description": "PLX-4720",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/793"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/794",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/98/summary#evidence",
				"source": "civic",
				"description": "Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.",
				"drug_labels": "CAPECITABINE,VEMURAFENIB,BEVACIZUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/756",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/794"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/794",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22180495"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "98",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/794"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/645",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "BEVACIZUMAB",
						"envcontext_id": "CHEMBL1201583",
						"usan_stem": "monoclonal antibodies",
						"description": "BEVACIZUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/794"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/644",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/794"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/643",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "CAPECITABINE",
						"envcontext_id": "60953",
						"usan_stem": "nucleoside antiviral or antineoplastic agents, cytarabine or azarabine derivatives",
						"description": "CAPECITABINE",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/794"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/795",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/99/summary#evidence",
				"source": "civic",
				"description": "Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/757",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/795"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/795",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22180495"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "99",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/795"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/646",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/795"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/796",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/126/summary#evidence",
				"source": "civic",
				"description": "Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF.",
				"drug_labels": "CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/758",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/796"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/796",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20619739"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "126",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/796"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/647",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/796"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/797",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/86/summary#evidence",
				"source": "civic",
				"description": "In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.",
				"drug_labels": "TRAMETINIB,391210-10-9",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/759",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/797"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/797",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24576830"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "86",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/797"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/649",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "391210-10-9",
						"envcontext_id": "CID9826528",
						"usan_stem": null,
						"description": "391210-10-9",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/797"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/648",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/797"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/798",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3736/summary#evidence",
				"source": "civic",
				"description": "In metastatic colorectal cancer patients with wildtype KRAS status who received cetuximab therapy, those with a BRAF V600E mutation had reduced progression-free survival (8.0wk vs. 31.4wk, P=0.001, log-rank test, univariate analysis) and reduced overall survival (6.5mo vs. 14.8mo, P=0.001, log-rank test, univariate analysis; HR:6.6, 95%CI:2.4-18.2, P<0.001, multivariate analysis. Similar associations have been found in independent studies.",
				"drug_labels": "CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/760",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/798"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/798",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19884556"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3736",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/798"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/650",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/798"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/799",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3738/summary#evidence",
				"source": "civic",
				"description": "Among metastatic colorectal cancer patients treated with cetuximab and irinotecan, those with BRAF V600E mutations were less likely to achieve a complete or partial response to therapy (0% , P=0.016, Fishers exact test) and had shorter median overall survival (4.1mo vs. 13.9mo, HR:0.51, 95%CI:0.18-0.95, P=0.037) than patients with wildtype BRAF.",
				"drug_labels": "CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/761",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/799"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/799",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19603018"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3738",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/799"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/651",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/799"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/800",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3739/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E (n=14) mutation treated with FOLFOX4 plus cetuximab were associated with a decreased progression free survival (7.2mo vs. 9.7mo, HR:0.39, 95% CI:0.21-0.72, P=0.0017), and decreased overall survival (11.7mo vs. 28.5mo, HR:0.23, 95% CI:0.12-0.41, P<0.0001), as compared to patients with wildtype BRAF.",
				"drug_labels": "CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/762",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/800"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/800",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25666295"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3739",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/800"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/652",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/800"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/801",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3740/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 53, KRAS exon 2 wild-type, metastatic colorectal cancer patients, patients harboring BRAF G466A (n=1), G469A (n=2), D594G (n=1), or V600E (n=2) mutations were reported to be non-responders to cetuximab in combination with irinotecan, (BRAF mutation positive: responders vs. non-responders = 0 vs. 6; BRAF wild-type: responders vs. non-responders 30 vs. 17; P=0.004), as compared to patients with wild-type BRAF.",
				"drug_labels": "CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/763",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/801"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/801",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26989027"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3740",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/801"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/653",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/801"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/802",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3741/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, WiDr, HT-29, LS411N, and SW1417 cell lines expressing BRAF V600E and treated with vemurafenib and erlotinib, or vemurafenib and gefitinib were associated with a reduction in cell viability (P<0.01), as compared to cells treated solely with vemurafenib or vehicle. WiDr and HT-29 cell lines expressing BRAF V600E were associated with a modest reduction in cell viability. Sensitivity was determined by assessing cell viability after 72h of vemurafenib treatement. In an in vivo study, WiDr and HT-29 xenografts expression BRAF V600E and treated with vemurafenib and erlotinib combination therapy were associated with reduced tumor volume (P<0.05) as compared to xenografts treated with vemurafenib alone, erlotinib alone, or vehicle alone.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/764",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/802"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/802",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22448344"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3741",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/802"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/654",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/802"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/803",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3742/summary#evidence",
				"source": "civic",
				"description": "In a clinical study of 122 cancer patients, including 37 previously treated colorectal cancer patients harboring BRAF V600 (V600E=32; V600 unknown=5) mutations, stable disease and progressive disease were reported in 50% of patients (n=5/10) treated with vemurafenib monotherapy, respectively.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/765",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/803"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/803",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26287849"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3742",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/803"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/655",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/803"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/804",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3743/summary#evidence",
				"source": "civic",
				"description": "An anaplastic thyroid cancer patient harboring BRAF V600E mutation was associated with response to vemurafenib treatment. The patient was initially treated with paclitaxel, but experienced disease progression; subsequently, the patient was treated concurrently with vemurafenib and radiation therapy and achieved regression of metastatic disease.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": null,
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/766",
						"source": "http://purl.obolibrary.org/obo/DOID_3963",
						"term": "thyroid carcinoma",
						"pheno_id": "DOID:3963",
						"family": "endocrine gland cancer",
						"description": "thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/804"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/804",
						"type": "Predictive",
						"description": null,
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23406047"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3743",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/804"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/656",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/804"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/805",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3744/summary#evidence",
				"source": "civic",
				"description": "In an anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification of the BRAF V600E mutation, the patient was treated with 6 cycles of standard chemotherapy plus radiation and experienced progressive disease; subsequently, the patient achieved a complete response with 61 weeks of vemurafenib monotherapy followed by disease progression.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": null,
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/767",
						"source": "http://purl.obolibrary.org/obo/DOID_3963",
						"term": "thyroid carcinoma",
						"pheno_id": "DOID:3963",
						"family": "endocrine gland cancer",
						"description": "thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/805"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/805",
						"type": "Predictive",
						"description": null,
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27532222"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3744",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/805"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/657",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/805"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/806",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3745/summary#evidence",
				"source": "civic",
				"description": "Acquired resistance to vemurafenib in BRAF V600E-positive melanomas frequently confound vemurafenib therapy. Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib resistant melanoma patients.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/768",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/806"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/806",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21107320"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3745",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/806"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/658",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/806"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/807",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3746/summary#evidence",
				"source": "civic",
				"description": "Acquired resistance to vemurafenib in BRAF V600E-positive melanomas frequently confound vemurafenib therapy. Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib resistant melanoma patients.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/769",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/807"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/807",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21107323"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3746",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/807"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/659",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/807"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/808",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3747/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, cell lines (including YUHUY and YUSAC2) expressing BRAF V600E were associated with increased sensitivity to vemurafenib (PLX4032) treatment, as compared to cell lines expressing wild-type BRAF. Sensitive was determined by assessing cellular proliferation, and ERK and MEK phosphorylation.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/770",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/808"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/808",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20149136"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3747",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/808"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/660",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/808"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/809",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3748/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/771",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/809"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/809",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3748",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/809"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/661",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/809"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/810",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3749/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 30 metastatic melanoma patients with progressing metastases, patients with BRAF V600E mutation (n=8) treated with vemurafenib monotherapy achieved a partial response (n=5) and stable disease (n=1).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/772",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/810"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/810",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24463458"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3749",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/810"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/662",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/810"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/811",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/757/summary#evidence",
				"source": "civic",
				"description": "One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled.",
				"drug_labels": "PICTILISIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/773",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/811"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/811",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25370471"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "757",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/811"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/663",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "PICTILISIB",
						"envcontext_id": "17755052",
						"usan_stem": "phosphatidylinositol 3-kinase inhibitors",
						"description": "PICTILISIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/811"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/812",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3750/summary#evidence",
				"source": "civic",
				"description": "In a phase 2 clinical trial (NCT00949702) of 132 BRAF mutation positive metastatic melanoma patients treated with vemurafenib monotherapy, patients harboring BRAF V600E (n=123) or V600K (n=9) mutations were associated with a favorable objective response rate (53% per RECIST v1.1 criteria, 70/132), with 6% (8/132) and 47% (62/132) of patients achieving complete response and partial response, respectively.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/774",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/812"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/812",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23569304"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3750",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/812"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/664",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/812"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/813",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3751/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, BRAF V600E expressing cell lines (COLO205, A375 and COLO829) demonstrated improved sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells. Sensitivity was determined by assessing cell proliferation (COLO205, GI50: 0.31uM; A375, GI50: 0.50 uM; COLO829, GI50: 1.7 uM vs. BRAF expressing cells (n=9) GI50: 10-41uM) and ERK phosphorylation.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/775",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/813"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/813",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18287029"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3751",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/813"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/665",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/813"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/814",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3752/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a MBA72 cell line expressing BRAF V600E demonstrated improved sensitivity to vemurafenib treatment, compared to LND-1 cells expression BRAF wild-type. Sensitivity was determined by assessing cell proliferation (MBA72, IC50: 3.2uM; vs. LND-1, IC50: 32.2 uM).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/776",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/814"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/814",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26070258"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3752",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/814"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/666",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/814"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/815",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3753/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, several cell lines (including MALME-3M, Colo829, Colo38, A375 and SK-MEK28) expressing BRAF V600E were associated with increased sensitivity to vemurafenib (RG7204) treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity was determined by proliferation assay and by assessing MEK1/2 phosphorylation. Further, in an in vivo study, LOX, Colo829 and A375 xenografts were reportedly sensitive to vemurafenib treatment as assessed by tumor volume.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/777",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/815"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/815",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20551065"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3753",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/815"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/667",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/815"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/816",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3754/summary#evidence",
				"source": "civic",
				"description": "In a stage I melanoma patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient enrolled in a clinical trial and was treated with vemurafenib monotherapy, a partial response was reported. However, novel hypermetabolic nodules developed and the patient enrolled in another clinical trial, undergoing combination therapy of vemurafenib and GDC-0973, but disease progression occurred at 5 months. Subsequently, the patient was treated with vemurafenib and ipilimumab, achieving a confirmed complete response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/778",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/816"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/816",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24616537"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3754",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/816"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/668",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/816"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/817",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3755/summary#evidence",
				"source": "civic",
				"description": "In a  clinical study of Polish, stage IIIC/IV, melanoma patients with metastases (n=75) harboring BRAF V600 mutation (as detected by cobas 4800 BRAF V600 Mutation Test), patients were associated with a 61.9% (95% CI: 50.1-73.6) median overall survival, a 7.4 months (95% CI: 5.5-9.2) median progression free survival; a median duration response of 7.4 months was reported, with 3% (2/75) and 43% (29/75) of patients achieving a complete and partial response, respectively.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/779",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/817"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/817",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26557775"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3755",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/817"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/669",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/817"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/818",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3756/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study of 27 melanoma cell lines, 18 out of 20 cell lines expressing BRAF V600E mutation were associated with sensitivity to vemurafenib treatment (IC50: 0.01-1M). Sensitivity was determined by assessing growth inhibition.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/780",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/818"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/818",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22241959"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3756",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/818"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/670",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/818"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/819",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3757/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 300 stage IV melanoma patients, patients with BRAF V600E mutation (n=175) were associated with a 4.8% (8/167) complete response, a 58.1% (97/167) partial response and stable disease in 22.2% (37/167) of cases; however, 15% (25/167) of patients harboring BRAF V600E experienced progressive disease.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/781",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/819"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/819",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25524477"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3757",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/819"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/671",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/819"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/820",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3759/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, a melanoma cell line, A375, expressing the BRAF V600E mutation was associated with resistance to dasatinib treatment, comparable to melanoma MEWO cells expressing wild-type BRAF. Resistance was determined by assessing cell viability.",
				"drug_labels": "DASATINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "resistant",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/782",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/820"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/820",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19671763"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3759",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/820"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/672",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DASATINIB",
						"envcontext_id": "3062316",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "DASATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/820"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/821",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3760/summary#evidence",
				"source": "civic",
				"description": "Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to vemurafenib than those with wildtype BRAF (IC50: 0.115 1.156 uM vs. 56.6741349.788 uM).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/783",
						"source": "http://purl.obolibrary.org/obo/DOID_1781",
						"term": "thyroid cancer",
						"pheno_id": "DOID:1781",
						"family": "endocrine gland cancer",
						"description": "thyroid cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/821"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/821",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18458053"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3760",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/821"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/673",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/821"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/822",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3761/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, the HCC364 cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability, apoptosis and colony formation.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/784",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/822"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/822",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25706985"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3761",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/822"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/674",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/822"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/823",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3762/summary#evidence",
				"source": "civic",
				"description": "In a mouse xenograft model, tumors derived from the glioblastoma cell line AM-38 that were treated with vemurafenib had reduced tumor growth and improved survival compared to control treated mice (P=0.018 and 0.0002, respectively). In contrast, mice with wildtype BRAF xenografts did not respond vemurafenib compared to control treatment as measured by tumor size and survival (P=0.179 and P=0.225, respectively ). A malignant astrocytoma cell line that expressed BRAF V600E was more sensitive to growth inhibition by vemurafenib than a cell line with wildtype BRAF (EC50=1.75 vs. 31.2 umol/L).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/785",
						"source": "http://purl.obolibrary.org/obo/DOID_3070",
						"term": "malignant glioma",
						"pheno_id": "DOID:3070",
						"family": "cell type cancer",
						"description": "malignant glioma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/823"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/823",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22038996"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3762",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/823"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/675",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/823"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/824",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3766/summary#evidence",
				"source": "civic",
				"description": "In a refractory hairy cell leukemia patient harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initially treated with conventional treatments and failed to respond; subsequently, the patient was treated with vemurafenib monotherapy and achieved complete remission on day 43 with treatment being terminated at day 56.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/786",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/824"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/824",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22621641"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3766",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/824"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/676",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/824"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/825",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3767/summary#evidence",
				"source": "civic",
				"description": "In a case report, a hairy cell leukemia (HCL) patient harboring BRAF V600E mutation was associated with a complete response to vemurafenib monotherapy after 3 months of treatment, which was sustained after 21 days of therapy. Prior to vemurafenib treatment, the patient had been diagnosed with HCL and achieved a complete hematologic response to splenectomy and interferon treatment, however, the patient subsequently relapsed and was treated with standard chemotherapy with further disease progression. As a follow-up to a previous study (23300174), a hairy cell leukemia patient harboring BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was previously treated with vemurafenib and obtained a complete response, but then experienced disease progression. Subsequently, the patient was re-treated with vemurafenib and again achieved a complete hematological response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/787",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/825"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/825",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23300174"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3767",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/825"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/677",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/825"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/826",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3768/summary#evidence",
				"source": "civic",
				"description": "In a hairy cell leukemia patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with 3 lines of chemotherapy, including 6 cycles of pentostatin and rituximab combination therapy, but experience progressive disease; subsequently, the patient was treated with vemurafenib monotherapy for 58 days and achieved a partial response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/788",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/826"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/826",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23278307"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3768",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/826"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/678",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/826"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/827",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3769/summary#evidence",
				"source": "civic",
				"description": "As a follow-up to a previous study (23300174), a hairy cell leukemia patient harboring BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was previously treated with vemurafenib and obtained a complete response, but then experienced disease progression. Subsequently, the patient was re-treated with vemurafenib and again achieved a complete hematological response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/789",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/827"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/827",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25815361"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3769",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/827"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/679",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/827"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/828",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3770/summary#evidence",
				"source": "civic",
				"description": "A hairy cell leukemia patient with extensive CNS involvement patient harboring BRAF V600E mutation was associated with complete response to vemurafenib monotherapy. Upon identification of the BRAF V600E mutation, the patient was treated with cytarabine, rituximab and methotrexate but quickly progressed; subsequently, the patient was treated with 2 rounds of vemurafenib and achieved complete response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/790",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/828"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/828",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27116997"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3770",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/828"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/680",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/828"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/829",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3771/summary#evidence",
				"source": "civic",
				"description": "In a case study, a pediatric grade IV glioblastoma multiforme patient harboring BRAF V600E mutation was associated with a complete response to vemurafenib monotherapy after 4 months of treatment, which was sustained at 6 month of therapy; the patient was undergoing the 7th cycle of therapy at the time of publication of this study.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/791",
						"source": "http://purl.obolibrary.org/obo/DOID_3068",
						"term": "glioblastoma multiforme",
						"pheno_id": "DOID:3068",
						"family": "malignant glioma",
						"description": "glioblastoma multiforme",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/829"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/829",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24725538"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3771",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/829"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/681",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/829"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/830",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3772/summary#evidence",
				"source": "civic",
				"description": "A pediatric pilocytic astrocytoma patient harboring BRAF V600E mutation, BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy regimens prior to the identification of the BRAF V600E mutation; subsequently, vemurafenib was administered (initially in combination with standard chemotherapy) and an overall regression achieved, with lack of disease progression noted at 15 months of vemurafenib therapy.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/792",
						"source": "http://purl.obolibrary.org/obo/DOID_4851",
						"term": "pilocytic astrocytoma",
						"pheno_id": "DOID:4851",
						"family": "malignant glioma",
						"description": "pilocytic astrocytoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/830"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/830",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24821190"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3772",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/830"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/682",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/830"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/831",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3773/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 17 papillary thyroid cancer patients, patients with BRAF V600E mutation (n=6) were associated with a 47% (7/15) partial response rate and a 53% (8/15) stable disease rate.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/793",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/831"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/831",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25353071"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3773",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/831"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/683",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/831"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/832",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3774/summary#evidence",
				"source": "civic",
				"description": "In a clinical trial (NCT01286753) of 55 cancer patients with BRAF V600E mutation, patients with metastatic papillary thyroid cancer (n=3) were associated with sensitivity to vemurafenib treatment. One patient achieved partial response (31% reduction by RECIST) and two patients achieved stable disease (9% and 16% reduction by RECIST criteria), the time to progression for these three patients was 11.7, 13.2 and 11.4 months, and the overall survival was 15 months (patient was subsequently treated with radiation therapy), at least 31.7 months (patient subsequently underwent laryngectomy) and 24.9 months (patient was subsequently treated with sorafenib, followed by sunitinib monotherapy), respectively.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/794",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/832"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/832",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23489023"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3774",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/832"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/684",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/832"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/833",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3775/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cell growth inhibition. In an in vivo experiment, dasatinib also inhibited the growth of K2 thyroid carcinoma xenografts in 7 of 13 mice.",
				"drug_labels": "DASATINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/795",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/833"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/833",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23729178"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3775",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/833"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/685",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DASATINIB",
						"envcontext_id": "3062316",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "DASATINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/833"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/834",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3776/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, WiDr, HT-29 and RKO cell lines expressing BRAF V600E mutation was associated with sensitivity to regorafenib treatment, as compared to Caco-2 and KM12SM cells expressing wild-type BRAF. Resistance was determined by assessing cell proliferation and migration.",
				"drug_labels": "REGORAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/796",
						"source": "http://purl.obolibrary.org/obo/DOID_219",
						"term": "colon cancer",
						"pheno_id": "DOID:219",
						"family": "intestinal cancer",
						"description": "colon cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/834"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/834",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26865419"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3776",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/834"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/686",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "REGORAFENIB",
						"envcontext_id": "11167602",
						"usan_stem": "raf kinase inhibitors",
						"description": "REGORAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/834"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/835",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3777/summary#evidence",
				"source": "civic",
				"description": "In a case report, a cervicomedullary ganglioglioma patient harboring BRAF V600E mutation was associated with radiological and clinical response to vemurafenib monotherapy after 3 months of treatment, which was sustained after 6 months of therapy. Prior to vemurafenib treatment, the patient had undergone tracheotomy, was treated with standard chemotherapy and underwent another surgery, but had developed progressive disease.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/797",
						"source": "http://purl.obolibrary.org/obo/DOID_5078",
						"term": "ganglioglioma",
						"pheno_id": "DOID:5078",
						"family": "cell type benign neoplasm",
						"description": "ganglioglioma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/835"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/835",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25524464"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3777",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/835"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/687",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/835"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/836",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3778/summary#evidence",
				"source": "civic",
				"description": "A grade I refractory brainstem ganglioglioma patient harboring BRAF V600E mutation was associated with partial response to vemurafenib monotherapy. The patient experienced significant clinical improvement in response to vemurafenib and maintained a partial response for 12 months; however, disease progression occurred after vemurafenib was discontinued for three months, reintroduction of vemurafenib resulted in a rapid partial response, with continued response noted at time of publication.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/798",
						"source": "http://purl.obolibrary.org/obo/DOID_5078",
						"term": "ganglioglioma",
						"pheno_id": "DOID:5078",
						"family": "cell type benign neoplasm",
						"description": "ganglioglioma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/836"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/836",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26579623"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3778",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/836"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/688",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/836"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/837",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3779/summary#evidence",
				"source": "civic",
				"description": "In a case report, a clear cell sarcoma patient harboring BRAF V600E mutation with distant metastases was associated with a complete response to vemurafenib monotherapy at 8 weeks of treatment. Prior to the administration of vemurafenib, the patient had undergone surgery and was treated with radiation, and standard chemotherapy, but had developed progressive disease.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/799",
						"source": "http://purl.obolibrary.org/obo/DOID_4233",
						"term": "clear cell sarcoma",
						"pheno_id": "DOID:4233",
						"family": "sarcoma",
						"description": "clear cell sarcoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/837"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/837",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26286452"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3779",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/837"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/689",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/837"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/838",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3780/summary#evidence",
				"source": "civic",
				"description": "In a lung adenocarcinoma patient with brain metastases harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. Upon treatment with vemurafenib monotherapy, the patients metastases demonstrated significant response and pleural right effusion improvement was observed; however, at 4 months the patients disease progressed resulting in death.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/800",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/838"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/838",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24888229"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3780",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/838"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/690",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/838"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/839",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3781/summary#evidence",
				"source": "civic",
				"description": "In a stage IV non-small cell lung cancer patient with a BRAF V600E mutation, who developed adenocarcinoma, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initially treated with four cycles of standard chemotherapy (cisplatin and pemetrexed) and achieved a partial response, subsequently a complete radiologic response was observed with 11 cycle of maintenance chemotherapy. However, the patients disease eventually progressed and lung adenocarcinoma and hepatic metastases were observed, the patient received radiotherapy, followed by the administration of vemurafenib monotherapy with concurrent radiotherapy, resulting in an excellent partial response followed by complete response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/801",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/839"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/839",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23733758"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3781",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/839"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/691",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/839"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/840",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3782/summary#evidence",
				"source": "civic",
				"description": "In a retrospective study of 35 lung adenocarcinoma patients (with chemotherapy previously administered in 86% of patients), patients harboring a BRAF V600E mutation and treated with vemurafenib monotherapy (n=29) were associated with an improved response rate; an overall survival (with 1st-line therapy) of 25.63 months, a 54% overall response rate and a 95% disease control rate were reported.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/802",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/840"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/840",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26200454"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3782",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/840"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/692",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/840"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/841",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3783/summary#evidence",
				"source": "civic",
				"description": "A stage IV lung adenocarcinoma patient harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patients prior treatment regimens were complex, including radiotherapy, standard chemotherapy and erlotinib; subsequently, the BRAF V600E mutation was identified and the patient was treated with vemurafenib monotherapy, achieving a favorable response for greater than 24 months.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/803",
						"source": "http://purl.obolibrary.org/obo/DOID_3910",
						"term": "lung adenocarcinoma",
						"pheno_id": "DOID:3910",
						"family": "respiratory system cancer",
						"description": "lung adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/841"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/841",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26776917"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3783",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/841"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/693",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/841"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/842",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3784/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, BRAF V600E expressing cell lines (BCPAP, OCUT1, K1 and SW1736) demonstrated increased sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells (FTC133, KAT18, Hth74 and WRO). Sensitivity was determined by assessing cell proliferation (OCUT1, IC50: 0.41uM; SW1736, IC50: 0.12 uM; K1, IC50: 0.83 uM; BCPAP, IC50: 1.16 uM vs. FTC133, IC50: 56.67 uM; KAT18, 541.66 uM; Hth74, IC50: 1349.79 uM; and WRO IC50: 943.73 uM) and ERK phosphorylation.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/804",
						"source": "http://purl.obolibrary.org/obo/DOID_3963",
						"term": "thyroid carcinoma",
						"pheno_id": "DOID:3963",
						"family": "endocrine gland cancer",
						"description": "thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/842"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/842",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21185263"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3784",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/842"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/694",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/842"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/843",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3785/summary#evidence",
				"source": "civic",
				"description": "In an in vitro study, the BCPAP cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability and apoptotic cell death. However, the 8505C cell line expressing a BRAF V600E mutation and high MET protein phosphorylation levels was reported to be insensitive to vemurafenib treatment.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/805",
						"source": "http://purl.obolibrary.org/obo/DOID_3963",
						"term": "thyroid carcinoma",
						"pheno_id": "DOID:3963",
						"family": "endocrine gland cancer",
						"description": "thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/843"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/843",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26456083"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3785",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/843"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/695",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/843"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/844",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3786/summary#evidence",
				"source": "civic",
				"description": "An anaplastic pleomorphic xanthoastrocytoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with radiation and temozolomide before experiencing disease progression; subsequent treatment with vemurafenib monotherapy, for a 12 week period, resulted in a near complete response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/806",
						"source": "http://purl.obolibrary.org/obo/DOID_4852",
						"term": "pleomorphic xanthoastrocytoma",
						"pheno_id": "DOID:4852",
						"family": "malignant glioma",
						"description": "pleomorphic xanthoastrocytoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/844"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/844",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25092772"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3786",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/844"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/696",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/844"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/845",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3787/summary#evidence",
				"source": "civic",
				"description": "A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard chemotherapy, hormone therapy and bevacizumab prior to the identification of the BRAF V600E mutation; next, the patient was treated with paclitaxel and an anti-HER3 antibody and finally with vemurafenib, obtaining a partial response of greater than 1 year.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/807",
						"source": "http://purl.obolibrary.org/obo/DOID_3605",
						"term": "ovarian cystadenocarcinoma",
						"pheno_id": "DOID:3605",
						"family": "ovary epithelial cancer",
						"description": "ovarian cystadenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/845"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/845",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26490654"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3787",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/845"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/697",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/845"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/846",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3788/summary#evidence",
				"source": "civic",
				"description": "In a malignant peripheral nerve sheath tumor patient harboring a BRAF V600E mutation, response to vemurafenib monotherapy was reported. Upon identification of the BRAF V600E mutation, the patient was treated with sorafenib monotherapy, but quickly progressed; subsequently, the patient was treated with vemurafenib. 33 days after treatment was initiated, tumor response was reported, as evident by the disappearance of chest and abdominal skin lesions.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/808",
						"source": "http://purl.obolibrary.org/obo/DOID_5940",
						"term": "malignant peripheral nerve sheath tumor",
						"pheno_id": "DOID:5940",
						"family": "peripheral nervous system neoplasm",
						"description": "malignant peripheral nerve sheath tumor",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/846"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/846",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24335681"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3788",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/846"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/698",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/846"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/847",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3789/summary#evidence",
				"source": "civic",
				"description": "A primary central nervous system (CNS)-histiocytic sarcoma patient harboring BRAF V600E mutation was associated with improved response to vemurafenib treatment. The patient was treated with vemurafenib monotherapy and obtained a clinical, biological and radiologic response; subsequently, the patient developed progressive disease and died 6 months after initial treatment with vemurafenib.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/809",
						"source": "http://purl.obolibrary.org/obo/DOID_4231",
						"term": "histiocytoma",
						"pheno_id": "DOID:4231",
						"family": "musculoskeletal system cancer",
						"description": "histiocytoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/847"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/847",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25209580"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3789",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/847"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/699",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/847"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/848",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3790/summary#evidence",
				"source": "civic",
				"description": "In a conjunctival malignant melanoma patient harboring a BRAF V600E mutation, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification of the BRAF V600E mutation, the patient was treated with cryotherapy, standard chemotherapy and whole brain radiotherapy; the patient achieved a 4 month progression free survival with vemurafenib treatment prior to disease progression.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/810",
						"source": "http://purl.obolibrary.org/obo/DOID_1751",
						"term": "malignant conjunctival melanoma",
						"pheno_id": "DOID:1751",
						"family": "sensory system cancer",
						"description": "malignant conjunctival melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/848"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/848",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27520988"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3790",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/848"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/700",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/848"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/849",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/816/summary#evidence",
				"source": "civic",
				"description": "This meta-analysis of 7 randomized control trials evaluating overall survival (OS) (8 for progression free survival) could not definitely state that survival benefit of anti-EGFR monoclonal antibodies is limited to patients with wild type BRAF. In other words, the authors believe that there is insufficient data to justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with mutant BRAF. In these studies, mutant BRAF specifically meant the V600E mutation.",
				"drug_labels": "CETUXIMAB,PANITUMUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/811",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/849"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/849",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25989278"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "816",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/849"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/702",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/849"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/701",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/849"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/850",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1398/summary#evidence",
				"source": "civic",
				"description": "The BRIM-3 Phase III trial NCT01006980 assessed BRAF inhibitor vemurafenib versus dacarbazine in 598 patients with treatment naive metastatic melanoma and confirmed V600E mutation. Significant differences were seen in overall survival (13.3 months with vemurafenib vs. 10.0 months with dacarbazine) and median progression free survival (6.9 months  with vemurafenib vs. 1.6 months with dacarbazine)",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/812",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/850"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/850",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24508103"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1398",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/850"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/703",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/850"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/851",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1405/summary#evidence",
				"source": "civic",
				"description": "In this Phase II pilot study (NCT00405587) of BRAF V600 inhibitor vemurafenib in 21 metastatic colorectal cancer (CRC) patients with BRAF V600E, one patient had a durable 21 week partial response, and seven patients had 8 week stable disease as best response. Median progression free survival was 2.1 months and median overall survival was 7.7 months. The authors conclude that single agent vemurafenib did not show meaningful activity in V600E CRC, in contrast to the significant vemurafenib activity against V600 in melanoma.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/813",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/851"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/851",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26460303"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1405",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/851"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/704",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/851"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/852",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1406/summary#evidence",
				"source": "civic",
				"description": "In trial NCT00880321, dabrafenib was tested in various solid tumor types harboring mutant BRAF after establishing dosage of 150 mg twice daily. In nine colorectal cancer patients with established V600E mutation, 1 confirmed response, 7 instances of stable disease, and 1 case of progressive disease was seen, which contrasted strongly with a 56% confirmed response rate seen in metastatic V600E melanoma patients similarly treated in the same study.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/814",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/852"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/852",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22608338"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1406",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/852"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/705",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/852"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/853",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1408/summary#evidence",
				"source": "civic",
				"description": "5 of 7 colorectal cancer (CRC) cell lines with BRAF V600E mutation were resistant to treatment with the BRAF inhibitor vemurafenib. An RNAi screen in the WiDr cell line (a V600E CRC line) identified EGFR as an enhancer for survival when exposed to vemurafenib.  Treatment with vemurafenib and EGFR inhibitor (cetuximab or gefitinib) in V600E CRC cells (WiDr, VACO432 and KM20) showed inhibited growth as well as induction of the cleaved PARP apoptotic marker. WiDr and VACO432 cells were injected into immunodeficient mice. Modest response was seen with vemurafenib treatment, while combination treatment showed considerable tumor growth inhibition as compared to control.",
				"drug_labels": "VEMURAFENIB,GEFITINIB,CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/815",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/853"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/853",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22281684"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1408",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/853"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/708",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/853"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/707",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GEFITINIB",
						"envcontext_id": "123631",
						"usan_stem": "tyrosine kinase inhibitors",
						"description": "GEFITINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/853"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/706",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/853"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/854",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1409/summary#evidence",
				"source": "civic",
				"description": "Phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. At 6 months, overall survival was 84% (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group. A relative reduction of 63% in the risk of death and of 74% in the risk of either death or disease progression was observed with vemurafenib as compared with dacarbazine (P<0.001 for both comparisons).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "A",
				"response_type": "Sensitivity/Response",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/816",
						"source": "http://purl.obolibrary.org/obo/DOID_8923",
						"term": "skin melanoma",
						"pheno_id": "DOID:8923",
						"family": "melanoma",
						"description": "skin melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/854"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/854",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21639808"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1409",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/854"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/709",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/854"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/855",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1410/summary#evidence",
				"source": "civic",
				"description": "Phase 2 trial in 132 patients with previously treated metastatic melanoma with BRAF V600E mutation. \nConfirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Median overall survival was 15.9 months (95% CI, 11.6 to 18.3).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/817",
						"source": "http://purl.obolibrary.org/obo/DOID_8923",
						"term": "skin melanoma",
						"pheno_id": "DOID:8923",
						"family": "melanoma",
						"description": "skin melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/855"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/855",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22356324"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1410",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/855"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/710",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/855"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/856",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1413/summary#evidence",
				"source": "civic",
				"description": "Treatment response to mutant BRAF inhibitor vemurafenib and EGFR inhibitor panitumumab was assayed in 12 patients with metastatic colorectal cancer (CRC) who had progressed on chemotherapy. Two patients had confirmed partial responses, and 2 showed stable disease over 6 months. The authors conclude that although some efficacy is seen, only a small subset of patients respond to this treatment and the responses are not durable.",
				"drug_labels": "VEMURAFENIB,PANITUMUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/818",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/856"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/856",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25589621"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1413",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/856"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/712",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/856"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/711",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/856"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/857",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1414/summary#evidence",
				"source": "civic",
				"description": "A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the only genetic alteration on a near diploid genome with trisomy 1q. Vemurafenib treatment resulted in improvement of symptoms and considerable reductions in tumor mass, and after 23 months the patient remained on therapy with well controlled disease.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/819",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/857"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/857",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24987354"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1414",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/857"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/713",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/857"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/858",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1421/summary#evidence",
				"source": "civic",
				"description": "In this Phase III trial (coBRIM, NCT01689519) of 495 V600 mutant melanoma patients, 344 had V600E mutation. 174 patients were treated with vemurafenib and placebo, and 170 were treated with vemurafenib and cobimetinib and tested for progression free survival. 88 of 174 monotherapy group patients had an event with median progression free survival of 6.5 months. In the combination group 58 of 174 patients had an event with median progression-free survival not met, however, when in combination with other V600 mutations median progression-free survival was 9.9 months with combination treatment. Median time to followup for the whole cohort was 7.3 months. Hazard Ratio for progression or death was 0.57 (0.41-0.80).",
				"drug_labels": "VEMURAFENIB,COBIMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/820",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/858"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/858",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25265494"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1421",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/858"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/715",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "COBIMETINIB",
						"envcontext_id": "16222096",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "COBIMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/858"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/714",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/858"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1428/summary#evidence",
				"source": "civic",
				"description": "In a mouse model of BRAF V600E colorectal cancer, western blots from tumors in mice treated with BRAF inhibitor GDC-0879 and PI3K/mTOR inhibitor BEZ235 showed stronger reduction in phospho-Akt and phospho-S6 than PI3K/mTOR inhibitor alone, and combination inhibition also resulted in stronger phospho-ERK inhibition in tumors than did BRAF inhibition alone. Increased apoptosis in tumors was seen in dual treatment conditions with increased TUNEL-positive cells. In vehicle treated mice, area of colon covered by tumor increased, while treatment with single agent inhibitors caused growth inhibition resulting in no change in colon area covered by tumors. Administration of dual inhibitors induced tumor regression apparent in a decrease of colonic area covered by tumors over the course of treatment.",
				"drug_labels": "NVP,DACTOLISIB,GDC,0879",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/821",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/859",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23549875"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1428",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/719",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "0879",
						"envcontext_id": "11717001",
						"usan_stem": null,
						"description": "0879",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/718",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GDC",
						"envcontext_id": "11717001",
						"usan_stem": null,
						"description": "GDC",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/717",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DACTOLISIB",
						"envcontext_id": "11977753",
						"usan_stem": "phosphatidylinositol 3-kinase inhibitors",
						"description": "DACTOLISIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/716",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "NVP",
						"envcontext_id": "44393931",
						"usan_stem": null,
						"description": "NVP",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/859"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/860",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1430/summary#evidence",
				"source": "civic",
				"description": "BRAF mutations were identified in 9% of 108 cases of high-grade colorectal neuroendocrine tumors (80% V600E). Two patients were treated with a combination of BRAF and MEK inhibition and exhibited durable response (beyond 7 and 9 months, respectively). Urinary BRAF V600E tumor DNA correlated with disease response in one of the patients. BRAF and MEK inhibition was either dabrafenib+trametinib (case 1) or vemurafenib+trametinib (case 2).",
				"drug_labels": "DABRAFENIB,TRAMETINIB,VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/822",
						"source": "http://purl.obolibrary.org/obo/DOID_0050626",
						"term": "gastrointestinal neuroendocrine tumor",
						"pheno_id": "DOID:0050626",
						"family": "gastrointestinal system cancer",
						"description": "gastrointestinal neuroendocrine tumor",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/860"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/860",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27048246"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1430",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/860"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/722",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/860"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/721",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/860"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/720",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/860"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/861",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1005/summary#evidence",
				"source": "civic",
				"description": "49 BRAF-mutant melanoma cell lines from patients not previously treated with BRAF inhibition were analyzed. 21 exhibited primary resistance to BRAF inhibition using PLX4720. Inhibition of MEK1/2 (BEZ235) and PI3K/mTOR (AZD6244 [selumetinib]) was the most effective approach to counteract resistance in comparison to inhibition with the PLX4720-BEZ235 (where response was assessed by apoptosis, viability, p-ERK, p-Akt inhibition).",
				"drug_labels": "SELUMETINIB,NVP,DACTOLISIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/823",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/861"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/861",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26678033"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1005",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/861"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/725",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DACTOLISIB",
						"envcontext_id": "11977753",
						"usan_stem": "phosphatidylinositol 3-kinase inhibitors",
						"description": "DACTOLISIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/861"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/724",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "NVP",
						"envcontext_id": "44393931",
						"usan_stem": null,
						"description": "NVP",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/861"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/723",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "SELUMETINIB",
						"envcontext_id": "10127622",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "SELUMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/861"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/862",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1579/summary#evidence",
				"source": "civic",
				"description": "Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia.  The overall response rate was 98% with 19/54 having a complete response and 34/54 having a partial response.  In the Italian study (n=25), the median relapse-free survival was 9 months and in the U.S. study (n=24), rate of progression-free survival was 73% with overall survival rate of 91%.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/824",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/862"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/862",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26352686"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1579",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/862"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/726",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/862"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/863",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1589/summary#evidence",
				"source": "civic",
				"description": "Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.",
				"drug_labels": "VEMURAFENIB,PANITUMUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/825",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/863"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/863",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27325282"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1589",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/863"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/728",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/863"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/727",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/863"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/864",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1591/summary#evidence",
				"source": "civic",
				"description": "Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort 1) previously been treated with VEGFR inhibitors.\n51 patients were enrolled (26 cohort 1, 25 cohort 2). In cohort 1, partial response was achieved in ten (38.5%) patients. Nine patients achieved stable disease for at least 6 months (35%). Median PFS was 18.2 months and median OS not reached after a median follow-up pf 18.8 months.\nIn cohort 2, six patients (27.3%) achieved a partial response and another six patients achieved stable disease for at least six months. Median PFS was 8.9 months and median OS was 14.4. months.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/826",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/864"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/864",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27460442"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1591",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/864"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/729",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/864"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/865",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1698/summary#evidence",
				"source": "civic",
				"description": "A 65-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and he received an autologous stem cell transplant. Sequencing of the recurrent tumor harbored BRAF V600E mutation and he was treated with vemurafenib.  After 7 weeks of treatment, the patient relapsed and died.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/827",
						"source": "http://purl.obolibrary.org/obo/DOID_9538",
						"term": "multiple myeloma",
						"pheno_id": "DOID:9538",
						"family": "bone marrow cancer",
						"description": "multiple myeloma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/865"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/865",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24997557"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1698",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/865"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/730",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/865"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/866",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1699/summary#evidence",
				"source": "civic",
				"description": "A 54-year-old man presented with stage II myeloma.  He was initially treated with chemotherapy and received an autologous stem cell transplant.  Genomic profiling of the bone biopsy revealed BRAF V600E activating mutation and the patient was treated with vemurafenib.  At 4-months post treatment (time of case study report) the patient maintains near-resolution of hypermetabolic lesions.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/828",
						"source": "http://purl.obolibrary.org/obo/DOID_9538",
						"term": "multiple myeloma",
						"pheno_id": "DOID:9538",
						"family": "bone marrow cancer",
						"description": "multiple myeloma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/866"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/866",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24997557"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1699",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/866"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/731",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/866"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/867",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1141/summary#evidence",
				"source": "civic",
				"description": "Preclinical study analyzing the differential response to MEK inhibitors in KRAS and BRAF mutant cancer cell lines and mouse xenografts. Inhibition of active, phosphorylated MEK by GDC-0973 (cobimetinib) is required for strong inhibition of the MAPK pathway in BRAF-mutant tumours. This study provides mechanistic rationale for improved efficacy of cobimetinib in BRAF-mutant models compared to MEK inhibitors acting through an alternative mechanism (GDC-0623 and G-573).",
				"drug_labels": "COBIMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/829",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/867"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/867",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23934108"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1141",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/867"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/732",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "COBIMETINIB",
						"envcontext_id": "16222096",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "COBIMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/867"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/868",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1749/summary#evidence",
				"source": "civic",
				"description": "Multicenter, phase 1, dose-escalation trial of PLX4032 (Vemurafenib). Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients. Patients without the V600E mutation had evidence of tumor regression.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/830",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/868"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/868",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20818844"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1749",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/868"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/733",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/868"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/869",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1902/summary#evidence",
				"source": "civic",
				"description": "Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 patients with colorectal cancer (1 with appendiceal cancer). Six of 17 evaluable patients achieved an objective response, 15 patients total had either stable disease or radiographic response (the patient with appendiceal cancer had disease progression). Estimated median PFS was 7.7 months. Effect of the combined treatment was also observed in xenograft and cell line studies.",
				"drug_labels": "VEMURAFENIB,CETUXIMAB,Irinotecan",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/831",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/869"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/869",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27729313"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1902",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/869"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/736",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Irinotecan",
						"envcontext_id": "60838",
						"usan_stem": "antineoplastics (camptothecine derivatives)",
						"description": "Irinotecan",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/869"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/735",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/869"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/734",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/869"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/870",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2115/summary#evidence",
				"source": "civic",
				"description": "In metastatic colorectal cancer patients with wildtype KRAS status, those with a BRAF V600E mutation were less likely to respond to treatment with cetuximab or panitumumab than  those with wildtype BRAF (0%  vs. 32% , P=0.029). Regardless of KRAS status, patients with BRAF mutations had reduced progression-free and overall survival (P=0.0107 and P <0.0001, respectively). Transfection of the colorectal cancer cell line DiFi with a BRAF V600E expression vector conferred decreased sensitivity to cetuximab and panitumumab in comparison to cells transfected with empty vector.",
				"drug_labels": "PANITUMUMAB,CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/832",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/870"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/870",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19001320"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2115",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/870"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/738",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/870"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/737",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/870"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/871",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2117/summary#evidence",
				"source": "civic",
				"description": "Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).",
				"drug_labels": "OXALIPLATIN",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/833",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/871"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/871",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19603024"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2117",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/871"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/739",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "OXALIPLATIN",
						"envcontext_id": "CHEMBL414804",
						"usan_stem": "antineoplastics (platinum derivatives)",
						"description": "OXALIPLATIN",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/871"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/872",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2118/summary#evidence",
				"source": "civic",
				"description": "The presence of BRAF V600E or D594K was associated with reduced progression-free survival in 5 patients with metastatic colorectal cancer treated with irinotecan-based first line therapy (3.5mo vs. 12.8mo, HR:4.1, 95%CI:1.5-11.3, P=0.006) when compared to 39 patients with wildtype BRAF.",
				"drug_labels": "Irinotecan",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/834",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/872"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/872",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19603024"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2118",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/872"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/740",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Irinotecan",
						"envcontext_id": "60838",
						"usan_stem": "antineoplastics (camptothecine derivatives)",
						"description": "Irinotecan",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/872"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/873",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2119/summary#evidence",
				"source": "civic",
				"description": "Among metastatic colorectal cancer patients treated with cetuximab and irinotecan, those with BRAF V600E mutations were less likely to achieve a complete or partial response to therapy (0% , P=0.016, Fishers exact test) and had reduced median overall survival (4.1mo vs. 13.9mo, HR:0.51, 95%CI:0.18-0.95, P=0.037) than patients with wildtype BRAF.",
				"drug_labels": "Irinotecan",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "resistant",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/835",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/873"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/873",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19603018"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2119",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/873"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/741",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Irinotecan",
						"envcontext_id": "60838",
						"usan_stem": "antineoplastics (camptothecine derivatives)",
						"description": "Irinotecan",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/873"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/874",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2121/summary#evidence",
				"source": "civic",
				"description": "In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=0.003) and reduced overall survival (15.0mo vs. 24.6mo, P=0.002) compared to those with wildtype BRAF.",
				"drug_labels": "BEVACIZUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/836",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/874"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/874",
						"type": "Predictive",
						"description": "Resistance",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19571295"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2121",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/874"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/742",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "BEVACIZUMAB",
						"envcontext_id": "CHEMBL1201583",
						"usan_stem": "monoclonal antibodies",
						"description": "BEVACIZUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/874"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/875",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2122/summary#evidence",
				"source": "civic",
				"description": "In a mouse in vivo study, the dual RAF and VEGF inhibitor sorafenib suppressed the growth of both UACC903 and 1205Lu cell line- generating  xenograft tumors harboring the BRAF-V600E mutation, which had a concomitant reduction of phosphorylated Erk-positive cells (P<0.05).",
				"drug_labels": "Sorafenib",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/837",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/875"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/875",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/15781657"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2122",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/875"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/743",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Sorafenib",
						"envcontext_id": "216239",
						"usan_stem": "raf kinase inhibitors",
						"description": "Sorafenib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/875"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/876",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2123/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model has shown a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "Sorafenib",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/838",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/876"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/876",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2123",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/876"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/744",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Sorafenib",
						"envcontext_id": "216239",
						"usan_stem": "raf kinase inhibitors",
						"description": "Sorafenib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/876"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/877",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2124/summary#evidence",
				"source": "civic",
				"description": "In a mouse in vivo study of MEK protein inhibitor, PD-0325901, was able to suppress growth of SKMEL28 BRAF-V600E xenograft tumors (P<0.01). The reduction of growth was associated with loss of D-cyclin expression and induction of p27.",
				"drug_labels": "0325901",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/839",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/877"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/877",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16273091"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2124",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/877"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/745",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "0325901",
						"envcontext_id": "9826528",
						"usan_stem": null,
						"description": "0325901",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/877"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/878",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2125/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "0325901",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/840",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/878"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/878",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2125",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/878"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/746",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "0325901",
						"envcontext_id": "9826528",
						"usan_stem": null,
						"description": "0325901",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/878"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/879",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2126/summary#evidence",
				"source": "civic",
				"description": "Patients with BRAF mutations who were treated with the specific RAF inhibitor dabrafenib had an improved overall survival (P<0.003) compared to untreated patients with BRAF mutations. Patients harboring BRAF mutations were associated with reduced overall survival (11.1mo vs. 46.1mo for wildtype, P=0.006).",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/841",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/879"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/879",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21343559"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2126",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/879"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/747",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/879"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/880",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2127/summary#evidence",
				"source": "civic",
				"description": "Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/842",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/880"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/880",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20818844"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2127",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/880"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/748",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/880"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/881",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2128/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/843",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/881"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/881",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2128",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/881"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/749",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/881"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/882",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2131/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "GSK",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/844",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/882"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/882",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2131",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/882"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/750",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "GSK",
						"envcontext_id": "15983966",
						"usan_stem": null,
						"description": "GSK",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/882"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/883",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2132/summary#evidence",
				"source": "civic",
				"description": "Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation, but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib-resistant melanoma patients.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/845",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/883"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/883",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21107323"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2132",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/883"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/751",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/883"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/884",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2133/summary#evidence",
				"source": "civic",
				"description": "Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/846",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/884"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/884",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21107320"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2133",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/884"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/752",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/884"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/885",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2134/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/847",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/885"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/885",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2134",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/885"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/753",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/885"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/886",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2135/summary#evidence",
				"source": "civic",
				"description": "In a study of 322 advanced melanoma patients with BRAF-V600E or BRAF-V600K mutations, treatment with trametinib was associated with improved progression-free survival (4.8mo vs. 1.5mo, <0.001) compared to chemotherapy control group. Additionally, treatment with trametinib was associated with increased 6-month overall survival (HR:0.54, 95% CI:0.32-0.92, P=0.01).",
				"drug_labels": "TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/848",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/886"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/886",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22663011"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2135",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/886"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/754",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/886"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/887",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2136/summary#evidence",
				"source": "civic",
				"description": "Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MAPK inhibitor CI-1040 than those with wildtype BRAF (IC50: 0.031-1.251 uM vs. 44.376-278.286 uM). In a mouse xenograft model, the growth of tumors derived from KAT10 cells, which carries the BRAF V600E mutation, was inhibited following treatment with CI-1040 (P<0.01), but drug treatment had no effect on growth of tumors derived from the MRO cell line, which expresses wildtype BRAF.",
				"drug_labels": "CI-1040",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/849",
						"source": "http://purl.obolibrary.org/obo/DOID_1781",
						"term": "thyroid cancer",
						"pheno_id": "DOID:1781",
						"family": "endocrine gland cancer",
						"description": "thyroid cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/887"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/887",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/17911174"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2136",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/887"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/755",
						"source": null,
						"term": "CI-1040",
						"envcontext_id": "",
						"usan_stem": "Uncategorized-ENV",
						"description": "CI-1040",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/887"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/888",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2137/summary#evidence",
				"source": "civic",
				"description": "In a study of 102 papillary thyroid cancer patients with a 15 year median follow-up time, those with BRAF V600E mutations had reduced overall survival compared to those with wildtype BRAF (P=0.015, log-rank test). The presence of BRAF V600E was associated with poorer outcome as defined by persistent disease or death (Odds ratio:14.63, 95%CI:1.28-167.29, P=0.03, multivariate analysis.",
				"drug_labels": "CI-1040",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/850",
						"source": "http://purl.obolibrary.org/obo/DOID_1781",
						"term": "thyroid cancer",
						"pheno_id": "DOID:1781",
						"family": "endocrine gland cancer",
						"description": "thyroid cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/888"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/888",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18682506"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2137",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/888"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/756",
						"source": null,
						"term": "CI-1040",
						"envcontext_id": "",
						"usan_stem": "Uncategorized-ENV",
						"description": "CI-1040",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/888"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/889",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2139/summary#evidence",
				"source": "civic",
				"description": "Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM).",
				"drug_labels": "119",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/851",
						"source": "http://purl.obolibrary.org/obo/DOID_1781",
						"term": "thyroid cancer",
						"pheno_id": "DOID:1781",
						"family": "endocrine gland cancer",
						"description": "thyroid cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/889"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/889",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21351275"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2139",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/889"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/757",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "119",
						"envcontext_id": "9549289",
						"usan_stem": null,
						"description": "119",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/889"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/890",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2142/summary#evidence",
				"source": "civic",
				"description": "Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001).",
				"drug_labels": "Sorafenib",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/852",
						"source": "http://purl.obolibrary.org/obo/DOID_1781",
						"term": "thyroid cancer",
						"pheno_id": "DOID:1781",
						"family": "endocrine gland cancer",
						"description": "thyroid cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/890"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/890",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16533790"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2142",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/890"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/758",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Sorafenib",
						"envcontext_id": "216239",
						"usan_stem": "raf kinase inhibitors",
						"description": "Sorafenib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/890"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/891",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2143/summary#evidence",
				"source": "civic",
				"description": "In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth assays of the HCC364 cell line (IC50=3.2 nmol/L). Additionally, cells exposed to PD-0325901 exhibited an increase in apoptosis, as measured by induction of PARP cleavage.",
				"drug_labels": "0325901",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/853",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/891"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/891",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19010912"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2143",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/891"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/759",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "0325901",
						"envcontext_id": "9826528",
						"usan_stem": null,
						"description": "0325901",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/891"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/892",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2146/summary#evidence",
				"source": "civic",
				"description": "In a phase 2 clinical trial  with 250 metastatic melanoma BRAF-V600E patients, treatment groups were randomly assigned to either dabrafenib, BRAF specific inhibitor, (n=187) or dacarbazine, a standard chemotherapeutic agent (n=63). Patients treated with dabrafenib were associated with improved progression-free survival (5.1mo vs. 2.7mo, HR:0.30, 95% CI:0.18-0.51, P<0.0001) compared with patients undergoing dacarbazine therapy.",
				"drug_labels": "DABRAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/854",
						"source": "http://purl.obolibrary.org/obo/DOID_8923",
						"term": "skin melanoma",
						"pheno_id": "DOID:8923",
						"family": "melanoma",
						"description": "skin melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/892"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/892",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22735384"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2146",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/892"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/760",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/892"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/893",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2894/summary#evidence",
				"source": "civic",
				"description": "Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.",
				"drug_labels": "Sorafenib,CETUXIMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/855",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/893"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/893",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/19001320"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2894",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/893"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/762",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "CETUXIMAB",
						"envcontext_id": "CHEMBL1201577",
						"usan_stem": "monoclonal antibodies",
						"description": "CETUXIMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/893"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/761",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Sorafenib",
						"envcontext_id": "216239",
						"usan_stem": "raf kinase inhibitors",
						"description": "Sorafenib",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/893"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/894",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3017/summary#evidence",
				"source": "civic",
				"description": "Patients with BRAF V600E-mutant NSCLC (n=57) were enrolled into a phase 2, multicentre, non-randomised, open-label study, administering dabrafenib plus trametinib. The overall response rate was 36/57 (63.2%, [95% CI 49.3-75.6]) and the median progression-free survival was 9.7 months (95% CI 6.9-19.6). At data cutoff (11.6 months of follow-up), 18/36  (50%) confirmed responses were ongoing and 23/57 (40%) of patients had died.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "A",
				"response_type": "Sensitivity/Response",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/856",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/894"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/894",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27283860"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3017",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/894"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/764",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/894"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/763",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/894"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/895",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2129/summary#evidence",
				"source": "civic",
				"description": "In a mouse in vivo study, the MEK protein inhibitor selumetinib suppressed the growth of 1205Lu xenograft tumors, which contains the BRAF-V600Emutation (0.91 +/- 0.10-fold volume increase vs. 9.47 +/- 2.14-fold for non-treated mice). These tumors had a concomitant reduction of BrdU positive cells (P=0.009) but no increase in apoptosis. Selumetinib, in combination with docetaxel, a chemotherapeutic agent, produced cycle arrest and elevated apoptosis.",
				"drug_labels": "SELUMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/857",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/895"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/895",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/18172275"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2129",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/895"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/765",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "SELUMETINIB",
						"envcontext_id": "10127622",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "SELUMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/895"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/896",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2130/summary#evidence",
				"source": "civic",
				"description": "An inducible BRAF-V600E mouse melanoma model has shown a tight correlation between activated BRAF and disease progression.",
				"drug_labels": "SELUMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/858",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/896"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/896",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/16424035"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2130",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/896"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/766",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "SELUMETINIB",
						"envcontext_id": "10127622",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "SELUMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/896"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/897",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2144/summary#evidence",
				"source": "civic",
				"description": "In a mouse xenograft model, tumors derived from pilocytic astrocytoma cells that expressed BRAF V600E experienced a complete response to treatment with selumetinib, whereas tumors derived from a wildtype BRAF pilocytic astrocytoma cell line were resistant to selumetinib.",
				"drug_labels": "SELUMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/859",
						"source": "http://purl.obolibrary.org/obo/DOID_3070",
						"term": "malignant glioma",
						"pheno_id": "DOID:3070",
						"family": "cell type cancer",
						"description": "malignant glioma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/897"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/897",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20806365"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2144",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/897"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/767",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "SELUMETINIB",
						"envcontext_id": "10127622",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "SELUMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/897"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/898",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2145/summary#evidence",
				"source": "civic",
				"description": "In a study of pediatric low-grade gliomas, BRAF V600E mutation was associated with a strong trend toward reduced progression free survival (HR:2.39, 95%CI:0.93-6.15, P=0.07, multivariate analysis).",
				"drug_labels": "SELUMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/860",
						"source": "http://purl.obolibrary.org/obo/DOID_3070",
						"term": "malignant glioma",
						"pheno_id": "DOID:3070",
						"family": "cell type cancer",
						"description": "malignant glioma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/898"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/898",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22492957"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2145",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/898"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/768",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "SELUMETINIB",
						"envcontext_id": "10127622",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "SELUMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/898"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/899",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5902/summary#evidence",
				"source": "civic",
				"description": "Chemotherapy-refractory, metastatic cholangiocarcinoma with BRAF V600E showed dramatically response for Dabrafenib and Trametinib combination.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/861",
						"source": "http://purl.obolibrary.org/obo/DOID_4947",
						"term": "cholangiocarcinoma",
						"pheno_id": "DOID:4947",
						"family": "bile duct cancer",
						"description": "cholangiocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/899"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/899",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/28480077"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5902",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/899"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/770",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/899"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/769",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/899"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/900",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5903/summary#evidence",
				"source": "civic",
				"description": "Two cases of patients with BRAF V600E positive cholangiocarcinoma showed excellent response for Dabrafenib and Trametinib.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/862",
						"source": "http://purl.obolibrary.org/obo/DOID_4947",
						"term": "cholangiocarcinoma",
						"pheno_id": "DOID:4947",
						"family": "bile duct cancer",
						"description": "cholangiocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/900"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/900",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/28078132"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5903",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/900"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/772",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/900"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/771",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/900"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/901",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5904/summary#evidence",
				"source": "civic",
				"description": "Dabrafenib and trametinib combination showed durable response for patients with standard chemotherapy refractory cholangiocarcinoma havoring BRAF V600E.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/863",
						"source": "http://purl.obolibrary.org/obo/DOID_4947",
						"term": "cholangiocarcinoma",
						"pheno_id": "DOID:4947",
						"family": "bile duct cancer",
						"description": "cholangiocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/901"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/901",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25435907"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5904",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/901"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/774",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/901"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/773",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/901"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/902",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5906/summary#evidence",
				"source": "civic",
				"description": "Patients with metastatic cholangiocarcinoma havoring with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. Multiple lung metastasis was dramatically regressed and this treatment was continued.",
				"drug_labels": "VEMURAFENIB,PANITUMUMAB,Irinotecan",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/864",
						"source": "http://purl.obolibrary.org/obo/DOID_4947",
						"term": "cholangiocarcinoma",
						"pheno_id": "DOID:4947",
						"family": "bile duct cancer",
						"description": "cholangiocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/902"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/902",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26687137"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5906",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/902"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/777",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "Irinotecan",
						"envcontext_id": "60838",
						"usan_stem": "antineoplastics (camptothecine derivatives)",
						"description": "Irinotecan",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/902"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/776",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/902"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/775",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/902"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/903",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5958/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\nWithin the BRAF mutant group, fourteen patients had refractory BRAF V600E-mutated NSCLC (adenocarcinoma, n = 13; sarcomatoid, n = 1). Six patients (43%; 95% CI, 18% to 71%) had objective responses (one CR, five PR), and two additional patients had SD > 120 days. The median DOR was 5 months (range, 4 to 14 months).",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/865",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/903"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/903",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5958",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/903"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/778",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/903"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/904",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5959/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively.\nAmong 4 patients with BRAF V600E mutant ovarian cancer, 2 had a partial response and one had stable disease > 120days.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/866",
						"source": "http://purl.obolibrary.org/obo/DOID_2394",
						"term": "ovarian cancer",
						"pheno_id": "DOID:2394",
						"family": "reproductive organ cancer",
						"description": "ovarian cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/904"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/904",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5959",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/904"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/779",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/904"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/905",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5960/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Among 2 patients with BRAF V600E mutant colorectal cancer, 1 had a partial response.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/867",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/905"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/905",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5960",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/905"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/780",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/905"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/906",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5961/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant anaplastic thyroid cancer had a complete response.",
				"drug_labels": "VEMURAFENIB,PERTUZUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/868",
						"source": "http://purl.obolibrary.org/obo/DOID_3963",
						"term": "thyroid carcinoma",
						"pheno_id": "DOID:3963",
						"family": "endocrine gland cancer",
						"description": "thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/906"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/906",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5961",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/906"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/782",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PERTUZUMAB",
						"envcontext_id": "CHEMBL2007641",
						"usan_stem": "monoclonal antibodies",
						"description": "PERTUZUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/906"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/781",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/906"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/907",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/5962/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient with BRAF V600E mutant laryngeal cancer had a partial response with vemurafenib.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "C",
				"response_type": "Sensitivity/Response",
				"evidence_level": "3",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/869",
						"source": "http://purl.obolibrary.org/obo/DOID_2876",
						"term": "laryngeal squamous cell carcinoma",
						"pheno_id": "DOID:2876",
						"family": "larynx cancer",
						"description": "laryngeal squamous cell carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/907"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/907",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5962",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/907"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/783",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/907"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/908",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/3758/summary#evidence",
				"source": "civic",
				"description": "In a clinical trial (NCT01597908) of 704 metastatic melanoma patients, patients harboring a BRAF V600E mutation and treated with vemurafenib (n=317) were associated with a 51% response rate, as compared to a 64% response rate (p<0.001) in V600E mutation positive patients treated with dabrafenib and trametinib combination therapy (n=312). Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/870",
						"source": "http://purl.obolibrary.org/obo/DOID_8923",
						"term": "skin melanoma",
						"pheno_id": "DOID:8923",
						"family": "melanoma",
						"description": "skin melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/908"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/908",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25399551"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "3758",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/908"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/785",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/908"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/784",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/908"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/909",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6045/summary#evidence",
				"source": "civic",
				"description": "In a phase 2 basket study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete response and one partial response was observed, for a response rate of 29%.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/871",
						"source": "MEDDRA",
						"term": "Anaplastic Thyroid Cancer",
						"pheno_id": "MEDDRA:10002240",
						"family": null,
						"description": "Anaplastic Thyroid Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/909"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/909",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/26287849"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6045",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/909"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/786",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/909"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/910",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6123/summary#evidence",
				"source": "civic",
				"description": "In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively.",
				"drug_labels": "DABRAFENIB,PANITUMUMAB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/872",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/910"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/910",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29431699"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6123",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/910"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/789",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/910"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/788",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/910"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/787",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/910"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/911",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6124/summary#evidence",
				"source": "civic",
				"description": "In this trial, 142 patients with metastatic, BRAF V600E mutant colorectal cancer were randomized to receive either BRAF inhibitor dabrafenib (D) + EGFR inhibitor panitumumab (P); or a triple therapy of D + P and MEK inhibition with trametinib (T) or T + P. Confirmed response rates for D+P (n=20), D+T+P (n=91), and T+P (n=31) were 10%, 21%, and 0%, respectively.",
				"drug_labels": "TRAMETINIB,PANITUMUMAB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/873",
						"source": "http://purl.obolibrary.org/obo/DOID_0050861",
						"term": "colorectal adenocarcinoma",
						"pheno_id": "DOID:0050861",
						"family": "large intestine cancer",
						"description": "colorectal adenocarcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/911"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/911",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29431699"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6124",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/911"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/791",
						"source": "http://rdf.ebi.ac.uk/terms/chembl",
						"term": "PANITUMUMAB",
						"envcontext_id": "CHEMBL1201827",
						"usan_stem": "monoclonal antibodies",
						"description": "PANITUMUMAB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/911"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/790",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/911"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/912",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6178/summary#evidence",
				"source": "civic",
				"description": "Adjuvant dual treatment with BRAF inhibitor dabrafenib and MEK inhibitor trametinib was administered to patients with stage III resected melenoma with V600E or V600K mutation in this stage III trial (COMBO-AD, NCT01682083). 792 (91%) patients had V600E, and were administered dabrafenib and trametinib or placebo for 12 months. In subsequent analysis, relapse or death occurred in 150/397 patients (38%) in the treatment group and 229/395 patients (58%) in the placebo group for a 95% CI Hazard Ratio of 0.48 (0.39-0.58).",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/874",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/912"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/912",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/28891408"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6178",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/912"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/793",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/912"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/792",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/912"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/913",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6938/summary#evidence",
				"source": "civic",
				"description": "In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and trametinib or dabrafenib alone with primary endpoint of progression free survival and secondary endpoints including disease response. The hazard ratio for progression or death in the V600E group was 0.81 for dabrafenib-trametinib vs dabrafenib-alone. Of 179 V600E patients in the dabrafenib-trametinib group, 68% of patients had a response, which was 15 percentage points higher than in the dabrafenib-alone group (95% CI, 4 to 24; P=0.006).",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/875",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/913"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/913",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25265492"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6938",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/913"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/795",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/913"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/794",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/913"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/914",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6940/summary#evidence",
				"source": "civic",
				"description": "In this Phase I and II study (NCT01072175) patients with metastatic melanoma were given dabrafenib and trametinib combination therapy vs. dabrafenib monotherapy. From V600E patients, 45 received monotherapy and 92 received combination therapy. Hazard ratio for progression or death was 0.43 (95% CI, 0.27-0.71). Both patients with the BRAF V600E and V600K mutation showed significant improvement in progression-free survival.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/876",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/914"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/914",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23020132"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6940",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/914"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/797",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/914"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/796",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/914"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/915",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/6975/summary#evidence",
				"source": "civic",
				"description": "Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anaplastic thyroid carcinoma responded to treatment (overall response rate 69%; 95% CI, 41% to 89%). Seven patients had ongoing responses.",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/877",
						"source": "http://purl.obolibrary.org/obo/DOID_3963",
						"term": "thyroid carcinoma",
						"pheno_id": "DOID:3963",
						"family": "endocrine gland cancer",
						"description": "thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/915"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/915",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29072975"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "6975",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/915"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/799",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/915"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/798",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/915"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/916",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/106/summary#evidence",
				"source": "civic",
				"description": "BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/878",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/916"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/916",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24396464"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "106",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/916"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/917",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/2503/summary#evidence",
				"source": "civic",
				"description": "In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001).",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/879",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/917"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/917",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21882184"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2503",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/917"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"source": "oncokb",
				"description": "FDA-approved biomarker and drug in this indication",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"evidence_label": "A",
				"response_type": "NA",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/1",
						"source": "MEDDRA",
						"term": "Anaplastic Thyroid Cancer",
						"pheno_id": "MEDDRA:10002240",
						"family": null,
						"description": "Anaplastic Thyroid Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/1",
						"type": "Predictive",
						"description": "1",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29072975"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "BRAF-Anaplastic Thyroid Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/2",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/1",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"source": "oncokb",
				"description": "FDA-approved biomarker and drug in this indication",
				"drug_labels": "VEMURAFENIB,DABRAFENIB,DABRAFENIB,TRAMETINIB,VEMURAFENIB,COBIMETINIB,TRAMETINIB,ENCORAFENIB,BINIMETINIB",
				"variant_name": "V600E",
				"source_link": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"evidence_label": "A",
				"response_type": "NA",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/3",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/3",
						"type": "Predictive",
						"description": "1",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29573941",
							"http://www.ncbi.nlm.nih.gov/pubmed/22735384",
							"http://www.ncbi.nlm.nih.gov/pubmed/28961848",
							"http://www.ncbi.nlm.nih.gov/pubmed/25265494",
							"http://www.ncbi.nlm.nih.gov/pubmed/25287827",
							"http://www.ncbi.nlm.nih.gov/pubmed/25399551",
							"http://www.ncbi.nlm.nih.gov/pubmed/22608338",
							"http://www.ncbi.nlm.nih.gov/pubmed/23051966",
							"http://www.ncbi.nlm.nih.gov/pubmed/28891408",
							"http://www.ncbi.nlm.nih.gov/pubmed/27480103",
							"http://www.ncbi.nlm.nih.gov/pubmed/22663011",
							"http://www.ncbi.nlm.nih.gov/pubmed/25265492",
							"http://www.ncbi.nlm.nih.gov/pubmed/24508103",
							"http://www.ncbi.nlm.nih.gov/pubmed/29361468",
							"http://www.ncbi.nlm.nih.gov/pubmed/28991513",
							"http://www.ncbi.nlm.nih.gov/pubmed/23020132"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "BRAF-Melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/4",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/5",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/6",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/7",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/8",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/9",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "COBIMETINIB",
						"envcontext_id": "16222096",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "COBIMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/10",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/11",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "ENCORAFENIB",
						"envcontext_id": "50922675",
						"usan_stem": "raf kinase inhibitors",
						"description": "ENCORAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/12",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "BINIMETINIB",
						"envcontext_id": "10288191",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "BINIMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/3"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/5",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"source": "oncokb",
				"description": "FDA-approved biomarker and drug in this indication",
				"drug_labels": "DABRAFENIB,TRAMETINIB",
				"variant_name": "V600E",
				"source_link": "http://oncokb.org/#/gene/BRAF/variant/V600E",
				"evidence_label": "A",
				"response_type": "NA",
				"evidence_level": "1",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/5",
						"source": "http://purl.obolibrary.org/obo/DOID_3908",
						"term": "non-small cell lung carcinoma",
						"pheno_id": "DOID:3908",
						"family": "lung cancer",
						"description": "non-small cell lung carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/5"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/5",
						"type": "Predictive",
						"description": "1",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27283860",
							"http://www.ncbi.nlm.nih.gov/pubmed/28919011"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "BRAF-Non-Small Cell Lung Cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/5"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/21",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/5"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/20",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/5"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/918",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/104/summary#evidence",
				"source": "civic",
				"description": "BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/880",
						"source": "http://purl.obolibrary.org/obo/DOID_1909",
						"term": "melanoma",
						"pheno_id": "DOID:1909",
						"family": "cell type cancer",
						"description": "melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/918"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/918",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24388723"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "104",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/918"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/919",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/102/summary#evidence",
				"source": "civic",
				"description": "Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/881",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/919"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/919",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24354346"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "102",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/919"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/920",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/656/summary#evidence",
				"source": "civic",
				"description": "In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T (N=35), recurrence-free survival is worse than in patients harboring one of these mutations (N=159 BRAF, N=26 TERT promoter mutated) or no mutations in either gene (N=287)(P<0.001).",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/882",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/920"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/920",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/25024077"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "656",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/920"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/921",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/107/summary#evidence",
				"source": "civic",
				"description": "V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/883",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/921"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/921",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21594703"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "107",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/921"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/922",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1552/summary#evidence",
				"source": "civic",
				"description": "In a study of 908 patients with colorectal cancer, 45 patients had BRAF V600E mutations and 589 patients were BRAF wild type.  BRAF V600E mutations were more likely to be proximal tumors (68.9%, 20.7%; p<0.0001), they were more likely to be poorly differentiated (17.7%, 1.9%; p<0.0001), they were more likely to be mucinous carcinoma type (20.0%, 4.2%; p=0.0003), they were more likely to have lymphatic invasion (77.6%, 49.9%; p=0.0003), and they had a shorter survival time (31.1 mo, 41.6 mo; p=0.001).  The 3-year survival rate was significantly poorer in the V600E group when compared to the wild type group (63.8%, 87.9%; p<0.0001).",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/884",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/922"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/922",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27404270"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1552",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/922"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/923",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1940/summary#evidence",
				"source": "civic",
				"description": "In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903).",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Negative",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/885",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/923"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/923",
						"type": "Prognostic",
						"description": "Negative",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/27302369"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1940",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/923"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/924",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/80/summary#evidence",
				"source": "civic",
				"description": "Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Positive",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/886",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/924"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/924",
						"type": "Diagnostic",
						"description": "Positive",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24570209"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "80",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/924"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/925",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/79/summary#evidence",
				"source": "civic",
				"description": "BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Positive",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/887",
						"source": "http://purl.obolibrary.org/obo/DOID_1781",
						"term": "thyroid cancer",
						"pheno_id": "DOID:1781",
						"family": "endocrine gland cancer",
						"description": "thyroid cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/925"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/925",
						"type": "Diagnostic",
						"description": "Positive",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21594703"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "79",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/925"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/926",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/463/summary#evidence",
				"source": "civic",
				"description": "In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/888",
						"source": "http://purl.obolibrary.org/obo/DOID_0070004",
						"term": "myeloid neoplasm",
						"pheno_id": "DOID:0070004",
						"family": "hematologic cancer",
						"description": "myeloid neoplasm",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/926"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/926",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/23612012"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "463",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/926"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/927",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/103/summary#evidence",
				"source": "civic",
				"description": "V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/889",
						"source": "http://purl.obolibrary.org/obo/DOID_9256",
						"term": "colorectal cancer",
						"pheno_id": "DOID:9256",
						"family": "intestinal cancer",
						"description": "colorectal cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/927"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/927",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/24594804"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "103",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/927"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/928",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/105/summary#evidence",
				"source": "civic",
				"description": "BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "resistant",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/890",
						"source": "http://purl.obolibrary.org/obo/DOID_3969",
						"term": "papillary thyroid carcinoma",
						"pheno_id": "DOID:3969",
						"family": "thyroid cancer",
						"description": "papillary thyroid carcinoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/928"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/928",
						"type": "Prognostic",
						"description": "Poor Outcome",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21594703"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "105",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/928"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/929",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/1",
					"name": "V600E",
					"description": "BRAF V600E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453136,
					"end_pos": 140453136,
					"ref": "A",
					"alt": "T",
					"hgvs_g": "NC_000007.13:g.140453136A>T",
					"hgvs_c": "NM_004333.4:c.1799T>A",
					"hgvs_p": "NP_004324.2:p.Val600Glu",
					"dbsnp_ids": [
						"113488022"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/12/summary/evidence/1127/summary#evidence",
				"source": "civic",
				"description": "In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients.",
				"drug_labels": null,
				"variant_name": "V600E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/12/summary",
				"evidence_label": "B",
				"response_type": "Positive",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/891",
						"source": "http://purl.obolibrary.org/obo/DOID_285",
						"term": "hairy cell leukemia",
						"pheno_id": "DOID:285",
						"family": "leukemia",
						"description": "hairy cell leukemia",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/929"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/929",
						"type": "Diagnostic",
						"description": "Positive",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21663470"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1127",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/929"
					}
				],
				"environmentalcontext_set": [

				]
			}
		],
		"name": "V600E",
		"description": "BRAF V600E",
		"biomarker_type": "missense_variant",
		"so_hierarchy": [
			"SO:0001060",
			"SO:0001537",
			"SO:0001878",
			"SO:0001564",
			"SO:0001576",
			"SO:0001791",
			"SO:0001580",
			"SO:0001818",
			"SO:0001650",
			"SO:0001992"
		],
		"soid": "SO:0001583",
		"so_name": "missense_variant",
		"reference_name": "GRCh37",
		"refseq": "NM_004333.4",
		"isoform": "ENST00000288602",
		"chromosome": "7",
		"start_pos": 140453136,
		"end_pos": 140453136,
		"ref": "A",
		"alt": "T",
		"hgvs_g": "NC_000007.13:g.140453136A>T",
		"hgvs_c": "NM_004333.4:c.1799T>A",
		"hgvs_p": "NP_004324.2:p.Val600Glu",
		"dbsnp_ids": [
			"113488022"
		],
		"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453136A>T?assembly=hg19",
		"gene": {
			"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
			"entrez_id": 673,
			"ensembl_gene_id": "ENSG00000157764",
			"symbol": "BRAF",
			"uniprot_ids": [
				"P15056"
			],
			"location": "7q34",
			"sources": {
				"civic": null,
				"oncokb": null
			}
		}
	},
	"65": {
		"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/65",
		"sources": [
			"civic",
			"oncokb"
		],
		"association_set": [
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/74",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/65",
					"name": "K601E",
					"description": "BRAF K601E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453134,
					"end_pos": 140453134,
					"ref": "T",
					"alt": "C",
					"hgvs_g": "NC_000007.13:g.140453134T>C",
					"hgvs_c": "NM_004333.4:c.1801A>G",
					"hgvs_p": "NP_004324.2:p.Lys601Glu",
					"dbsnp_ids": [
						"121913364"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453134T>C?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "http://oncokb.org/#/gene/BRAF/variant/K601E",
				"source": "oncokb",
				"description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved",
				"drug_labels": null,
				"variant_name": "K601E",
				"source_link": null,
				"evidence_label": null,
				"response_type": null,
				"evidence_level": null,
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/68",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/74"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/74",
						"type": "Predisposing",
						"description": "Gain-of-function",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/20179705",
							"http://www.ncbi.nlm.nih.gov/pubmed/26343582",
							"http://www.ncbi.nlm.nih.gov/pubmed/22798288",
							"http://www.ncbi.nlm.nih.gov/pubmed/28783719",
							"http://www.ncbi.nlm.nih.gov/pubmed/18794803",
							"http://www.ncbi.nlm.nih.gov/pubmed/26643848"
						],
						"evidenceType_sourceName": "oncokb",
						"evidenceType_id": "BRAF-Likely Oncogenic",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/74"
					}
				],
				"environmentalcontext_set": [

				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1005",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/65",
					"name": "K601E",
					"description": "BRAF K601E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453134,
					"end_pos": 140453134,
					"ref": "T",
					"alt": "C",
					"hgvs_g": "NC_000007.13:g.140453134T>C",
					"hgvs_c": "NM_004333.4:c.1801A>G",
					"hgvs_p": "NP_004324.2:p.Lys601Glu",
					"dbsnp_ids": [
						"121913364"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453134T>C?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/584/summary/evidence/5963/summary#evidence",
				"source": "civic",
				"description": "The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patients with BRAF V600E mutations, objective responses were seen in 12 patients (46%; 95% CI, 27% to 67%). Only one of 23 patients (4%; 95% CI, 0% to 22%) with other non-V600 BRAF mutations had a PR (pancreas cancer with a CUX1-BRAF fusion). Non-responding BRAF mutations included: K601E (n = 6), G464V (n = 2), G469A (n = 2), G496A (n = 2), N581S (n = 2), and one each for G466V, G596R, G606E, L597Q, P731T, intron 9 rearrangement, intron 10 rearrangement, and MACF1- and WASFL-BRAF fusion.",
				"drug_labels": "VEMURAFENIB",
				"variant_name": "K601E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/584/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/967",
						"source": "http://purl.obolibrary.org/obo/DOID_162",
						"term": "cancer",
						"pheno_id": "DOID:162",
						"family": "cancer",
						"description": "cancer",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1005"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/1005",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/29320312"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "5963",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1005"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/882",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1005"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1006",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/65",
					"name": "K601E",
					"description": "BRAF K601E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453134,
					"end_pos": 140453134,
					"ref": "T",
					"alt": "C",
					"hgvs_g": "NC_000007.13:g.140453134T>C",
					"hgvs_c": "NM_004333.4:c.1801A>G",
					"hgvs_p": "NP_004324.2:p.Lys601Glu",
					"dbsnp_ids": [
						"121913364"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453134T>C?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/584/summary/evidence/2812/summary#evidence",
				"source": "civic",
				"description": "In a study of 197 metastatic melanoma patients, BRAF mutations were identified in 95 patients including V600E (n=70), V600K (n=19), K601E (n=1) and D594N (n=1). Patients were treated with a specific RAF inhibitor (dabrafenib), which improved overall survival of patients with BRAF mutations (P<0.003), compared to non-treated patients with BRAF mutations. Patients having BRAF mutations without RAF inhibitor treatment were associated with reduced overall survival (11.1 mo vs. 46.1 mo for wild-type, P=0.006).",
				"drug_labels": "DABRAFENIB",
				"variant_name": "K601E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/584/summary",
				"evidence_label": "B",
				"response_type": "Sensitivity/Response",
				"evidence_level": "2",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/968",
						"source": "http://purl.obolibrary.org/obo/DOID_8923",
						"term": "skin melanoma",
						"pheno_id": "DOID:8923",
						"family": "melanoma",
						"description": "skin melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1006"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/1006",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/21343559"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "2812",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1006"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/883",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "DABRAFENIB",
						"envcontext_id": "44462760",
						"usan_stem": "raf kinase inhibitors",
						"description": "DABRAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1006"
					}
				]
			},
			{
				"url": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1007",
				"gene": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
					"entrez_id": 673,
					"ensembl_gene_id": "ENSG00000157764",
					"symbol": "BRAF",
					"uniprot_ids": [
						"P15056"
					],
					"location": "7q34",
					"sources": {
						"civic": null,
						"oncokb": null
					}
				},
				"variant": {
					"url": "https://svip-dev.nexus.ethz.ch/api/v1/variants/65",
					"name": "K601E",
					"description": "BRAF K601E",
					"biomarker_type": "missense_variant",
					"so_hierarchy": [
						"SO:0001060",
						"SO:0001537",
						"SO:0001878",
						"SO:0001564",
						"SO:0001576",
						"SO:0001791",
						"SO:0001580",
						"SO:0001818",
						"SO:0001650",
						"SO:0001992"
					],
					"soid": "SO:0001583",
					"so_name": "missense_variant",
					"reference_name": "GRCh37",
					"refseq": "NM_004333.4",
					"isoform": "ENST00000288602",
					"chromosome": "7",
					"start_pos": 140453134,
					"end_pos": 140453134,
					"ref": "T",
					"alt": "C",
					"hgvs_g": "NC_000007.13:g.140453134T>C",
					"hgvs_c": "NM_004333.4:c.1801A>G",
					"hgvs_p": "NP_004324.2:p.Lys601Glu",
					"dbsnp_ids": [
						"121913364"
					],
					"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453134T>C?assembly=hg19",
					"sources": {
						"civic": null,
						"oncokb": null
					},
					"gene": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1"
				},
				"source_url": "https://civicdb.org/events/genes/5/summary/variants/584/summary/evidence/1462/summary#evidence",
				"source": "civic",
				"description": "Preclinical study in 293H cell line. Ectopic expression of V600E, L597R/Q/S, and K601E mutants elevated phospho-MEK and ERK levels. Vemurafenib treatment of all of the BRAF mutantexpressing cells led to a decrease in phospho-MEK and ERK protein levels. Treatment with MEK inhibitor GSK1120212 led to a more dramatic decrease in phospho-ERK signaling.",
				"drug_labels": "TRAMETINIB,VEMURAFENIB",
				"variant_name": "K601E",
				"source_link": "https://civic.genome.wustl.edu/events/genes/5/summary/variants/584/summary",
				"evidence_label": "D",
				"response_type": "Sensitivity/Response",
				"evidence_level": "4",
				"phenotype_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/phenotypes/969",
						"source": "http://purl.obolibrary.org/obo/DOID_8923",
						"term": "skin melanoma",
						"pheno_id": "DOID:8923",
						"family": "melanoma",
						"description": "skin melanoma",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1007"
					}
				],
				"evidence_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/evidence_items/1007",
						"type": "Predictive",
						"description": "Sensitivity/Response",
						"publications": [
							"http://www.ncbi.nlm.nih.gov/pubmed/22798288"
						],
						"evidenceType_sourceName": "CIVIC",
						"evidenceType_id": "1462",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1007"
					}
				],
				"environmentalcontext_set": [
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/885",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "VEMURAFENIB",
						"envcontext_id": "42611257",
						"usan_stem": "raf kinase inhibitors",
						"description": "VEMURAFENIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1007"
					},
					{
						"url": "https://svip-dev.nexus.ethz.ch/api/v1/environmental_contexts/884",
						"source": "http://rdf.ncbi.nlm.nih.gov/pubchem/compound",
						"term": "TRAMETINIB",
						"envcontext_id": "11707110",
						"usan_stem": "tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors",
						"description": "TRAMETINIB",
						"association": "https://svip-dev.nexus.ethz.ch/api/v1/associations/1007"
					}
				]
			}
		],
		"name": "K601E",
		"description": "BRAF K601E",
		"biomarker_type": "missense_variant",
		"so_hierarchy": [
			"SO:0001060",
			"SO:0001537",
			"SO:0001878",
			"SO:0001564",
			"SO:0001576",
			"SO:0001791",
			"SO:0001580",
			"SO:0001818",
			"SO:0001650",
			"SO:0001992"
		],
		"soid": "SO:0001583",
		"so_name": "missense_variant",
		"reference_name": "GRCh37",
		"refseq": "NM_004333.4",
		"isoform": "ENST00000288602",
		"chromosome": "7",
		"start_pos": 140453134,
		"end_pos": 140453134,
		"ref": "T",
		"alt": "C",
		"hgvs_g": "NC_000007.13:g.140453134T>C",
		"hgvs_c": "NM_004333.4:c.1801A>G",
		"hgvs_p": "NP_004324.2:p.Lys601Glu",
		"dbsnp_ids": [
			"121913364"
		],
		"myvariant_hg19": "http://myvariant.info/v1/variant/chr7:g.140453134T>C?assembly=hg19",
		"gene": {
			"url": "https://svip-dev.nexus.ethz.ch/api/v1/genes/1",
			"entrez_id": 673,
			"ensembl_gene_id": "ENSG00000157764",
			"symbol": "BRAF",
			"uniprot_ids": [
				"P15056"
			],
			"location": "7q34",
			"sources": {
				"civic": null,
				"oncokb": null
			}
		}
	}	
}